

Bibliography

This bibliography is divided into four parts:

PART 1 - Original Peer Reviewed Papers

PART 2 - Reviews

PART 3 - Books

PART 4 - Edited Journal Issues

PART 1: Original Peer Reviewed Papers

1976

1. **Workman P**, Double JA, Ball CR. Enzyme-activated antitumour agents - II. The role of alkaline phosphatase in the release of p-hydroxyaniline mustard from its phosphate conjugate in cells in culture. *Biochem Pharmacol* 1976; 25:1139-44.
2. **Workman P**, Double JA, Wilman DEV. Enzyme-activated antitumour agents - III. Hydrolysis of conjugates of p-hydroxyaniline mustard in aqueous solution. *Biochem Pharmacol* 1976; 25:2347-50.

1977

3. Double JA, **Workman P**. A new high-glucuronidase tumour curable by aniline mustard therapy. *Cancer Treat Rep* 1977; 61:909-11.
4. Watson JV, Chambers SH, **Workman P**, Horsnell TS. A flow cytofluorimetric method for measuring enzyme reaction kinetics in intact cells. *FEBS Letters* 1977; 81:179-82.
5. **Workman P**. Enzyme-activated antitumour agents. PhD Thesis, University of Leeds 1977.

1978

6. Watson JV, **Workman P**, Chambers SH. Different esterase activities of exponential and plateau phases of EMT6 cells monitored by flow cytofluorimetry. *Br J Cancer* 1978; 37:397-402.
7. Wiltshire CR, **Workman P**, Watson JV, Bleehen NM. Clinical studies with misonidazole. *Br J Cancer Suppl* 1978; 3:286-9.
8. **Workman P**. Inhibition of human prostatic tumour acid phosphatases by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylamino-phenyl phosphate and other disfunctional nitrogen mustards. *Chem Biol Interactions* 1978; 20:103-12.
9. **Workman P**, Double JA. Enzyme-activated antitumor agents - IV. Comparative kinetics of N,pN-p-di-2-chloroethylaminophenyl phosphate hydrolysis catalysed by phosphatases of normal and neoplastic tissues. *Biochem Pharmacol* 1978; 27:199-202.
10. **Workman P**, Little CJ, Marten TR, Dale AD, Ruane RJ, Flockhart IR, Bleehen NM. Estimation of the hypoxic cell sensitizer misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. *J Chromatogr* 1978; 145:507-12.
11. **Workman P**, Wiltshire CR, Plowman PN, Bleehen NM. Monitoring of salivary misonidazole concentration in man: A possible alternative to plasma monitoring. *Br J Cancer* 1978; 38:709-18.

1979

12. Brown JM, Yu NM, **Workman P**. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. *Br J Cancer* 1979; 39:310-20.
13. Watson JV, **Workman P**, Chambers SH. An assay for plasma membrane phosphatase activity in populations of individual cells. *Biochem Pharmacol* 1979; 28:821-7.
14. White RAS, **Workman P**, Freedman LS, Owen LN, Bleehen NM. The pharmacokinetics of misonidazole in the dog. *Eur J Cancer* 1979; 15:1233-42.
15. White RAS, **Workman P**, Owen LN, Bleehen NM. The penetration of misonidazole into spontaneous canine tumours. *Br J Cancer* 1979; 40:284-94.
16. **Workman P**. Analysis of the basic 5-nitroimidazole nimorazole in blood by reversed-phase high-performance liquid chromatography, and its application to pharmacokinetic studies in individual mice. *J Chromatogr* 1979; 163:396-402.
17. **Workman P**. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. *Br J Cancer* 1979; 40:335-53.

1980

18. Brown JM, **Workman P**. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. *Radiat Res* 1980; 82:171-90.
19. Honess DJ, **Workman P**, Morgan JE, Bleehen NM. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetised mouse. *Br J Cancer* 1980; 41:529-40.
20. White RAS, **Workman P**. Pharmacokinetic and tumour penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-9963) in dogs. *Br J Cancer* 1980; 41:268-76.
21. White RAS, **Workman P**. Phenytoin-sodium induced alterations in the pharmacokinetics of misonidazole in the dog. *Cancer Treat Rep* 1980; 64:360-1.
22. White RAS, **Workman P**, Brown JM. The pharmacokinetics and tumour and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog - hydrophilic radiosensitizers potentially less toxic than misonidazole. *Radiat Res* 1980; 84:542-61.
23. **Workman P**. Drug interactions with misonidazole: Effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice. *Biochem Pharmacol* 1980; 29:2769-76.
24. **Workman P**. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. *Cancer Chemother Pharmacol* 1980; 5:27-37.
25. **Workman P**. The neurotoxicity of misonidazole: Potential modifying role of dexamethasone. *Br J Radiol* 1980; 53:736.
26. **Workman P**, Bleehen NM, Wiltshire CR. Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: Implications for possible reduced toxicity. *Br J Cancer* 1980; 41:302-4.

1981

27. **Workman P**, Brown JM. Structure-pharmacokinetic relationships for misonidazole analogues in mice. *Cancer Chemother Pharmacol* 1981; 6:39-49.

1982

28. Twentyman PR, **Workman P**. Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. *Br J Cancer* 1982; 45:447-55.
29. Twentyman PR, **Workman P**. The effect of radiosensitizer pretreatment on the response of the RIF-1 mouse sarcoma to cytotoxic drugs. *Int J Radiat Oncol Biol Phys* 1982; 8:611-3.
30. Warenius HM, **Workman P**, Bleehen NM. Response of a high-glucuronidase human tumour xenograft to aniline mustard. *Br J Cancer* 1982; 45:27-34.

31. White RAS, **Workman P**, Owen LN. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole. *Int J Radiat Oncol Biol Phys* 1982; 8:473-6.
32. **Workman P**, Twentyman PR. Enhancement by electron-affinic agents of the therapeutic effect of cytotoxic agents against the KHT tumor: Structure-activity relationships. *Int J Radiat Oncol Biol Phys* 1982; 8:623-6.
33. **Workman P**, Twentyman PR. Structure-activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. *Br J Cancer* 1982; 46:249-59.
34. **Workman P**, White RAS. Effects of the xanthine oxidase inhibitor allopurinol on the renal clearance of nitroimidazoles. *Biochem Pharmacol* 1982; 31:3041-6.

1983

35. Bleehen NM, Grant RM, Jones DH, Roberts JT, **Workman P**, Gleave JRW, Harding DG, Holmes AE. The penetration of misonidazole and desmethylmisonidazole into brain tumours and other central nervous system tissues in man. *Br J Radiol* 1983; 56:859-63.
36. Jones DH, Bleehen NM, **Workman P**, Smith NC. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity. *Br J Radiol* 1983; 56:865-70.
37. Jones DH, Bleehen NM, **Workman P**, Walton MI. The role of dexamethasone in the modification of misonidazole pharmacokinetics. *Br J Cancer* 1983; 48:553-7.
38. Lee FYF, **Workman P**. Modification of CCNU pharmacokinetics by misonidazole - a major mechanism of chemosensitization in mice. *Br J Cancer* 1983; 47:659-69.
39. Twentyman PR, **Workman P**. An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. *Br J Cancer* 1983; 47:187-94.
40. Twentyman PR, **Workman P**. Chemosensitization by lipophilic nitroimidazoles. *Br J Cancer* 1983; 48:17-26.
41. **Workman P**, Donaldson JA, Smith NC. Effects of cimetidine, antipyrine and pregnenolone carbonitrile on misonidazole pharmacokinetics. *Cancer Treat Rep* 1983; 67:723-5.
42. **Workman P**, Twentyman PR, Lee FYF, Walton MI. Drug metabolism and chemosensitization: Nitroimidazoles as inhibitors of drug metabolism. *Biochem Pharmacol* 1983; 32:857-64.

1984

43. Lee FYF, **Workman P**. Misonidazole and CCNU: Further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain. *Br J Cancer* 1984; 49:579-85.
44. Lee FYF, **Workman P**. Nitroimidazoles as modifiers of nitrosourea pharmacokinetics. *Int J Radiat Oncol Biol Phys* 1984; 10:1627-30.
45. Reeve JG, Wright KA, **Workman P**. Patterns of cross-sensitivity in the response of clonal subpopulations isolated from the RIF-1 mouse sarcoma to selected nitrosoureas and nitrogen mustards. *Br J Cancer* 1984; 50:153-8.
46. Roberts JT, Bleehen NM, Lee FYF, **Workman P**, Walton MI. A phase I study of the combination of benznidazole and CCNU in man. *Int J Radiat Oncol Biol Phys* 1984; 10:1745-8.
47. Roberts JT, Bleehen NM, **Workman P**, Walton MI. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799. *Int J Radiat Oncol Biol Phys* 1984; 10:1755-8.
48. **Workman P**, Walton MI. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069. *Int J Radiat Oncol Biol Phys* 1984; 10:1307-10.
49. **Workman P**, White RAS, Walton MI, Owen LN, Twentyman PR. Preclinical pharmacokinetics of benznidazole. *Br J Cancer* 1984; 50:291-303.

1985

50. Baillie-Johnson H, Twentyman PR, Fox NE, Walls GA, **Workman P**, Watson JV, Johnson N, Reeve JG, Bleehen NM. Establishment and characterization of cell lines from patients with small cell lung cancer. *Br J Cancer* 1985; 52:495-504.
51. Honess DJ, Donaldson JA, **Workman P**, Bleehen NM. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. *Br J Cancer* 1985; 51:77-84.

52. Lee FYF, **Workman P**, Roberts JT, Bleehen NM. Clinical pharmacokinetics of oral CCNU (Lomustine). *Cancer Chemother Pharmacol* 1985; 14:125-31.
53. Lee FYF, **Workman P**. Misonidazole protects tumour and normal tissues from the toxicity of oral CCNU. *Br J Cancer* 1985; 51:85-91.
54. Twentyman PR, **Workman P**, Wright KA, Bleehen NM. The effects of α and γ interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. *Br J Cancer* 1985; 52:21-9.
55. Walton MI, Bleehen NM, **Workman P**. The reversible N-oxidation of the nitroimidazole radiosensitizer Ro 03-8799. *Biochem Pharmacol* 1985; 34:3939-40.

1986

56. Lee FYF, Coe P, **Workman P**. Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenyl acetic mustard and β,β -difluorochlorambucil (CB 7103) in mice. *Cancer Chemother Pharmacol* 1986; 17:21-9.
57. Lee FYF, **Workman P**. Altered pharmacokinetics in the mechanism of chemosensitization: Effects of misonidazole and other modifiers on the pharmacokinetics and antitumour activity of selected nitrogen mustards. *Cancer Chemother Pharmacol* 1986; 17:30-7.
58. Lee FYF, **Workman P**. Interaction of nitroimidazole sensitizers with drug metabolizing enzymes - spectral and kinetic studies. *Int J Radiat Oncol Biol Phys* 1986; 12:1383-7.
59. Newman HFV, Bleehen NM, **Workman P**. A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: A preliminary report of single dose toxicity, pharmacokinetics and tumour concentrations. *Br J Radiol* 1986; 54:423-5.
60. Newman HFV, Bleehen NM, **Workman P**. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: Toxicity and pharmacokinetics. *Int J Radiat Oncol Biol Phys* 1986; 12:1113-6.
61. Newman HFV, Dunphy EP, Bleehen NM, Dische S, Saunders MI, Des Rochers C, **Workman P**, Lenox-Smith I. A comparative study of Ro 03-8799: Racemic mixture and enantiomers. *Br J Radiol* 1986; 59:997-9.
62. Roberts JT, Bleehen NM, Walton MI, **Workman P**. A clinical phase I toxicity study of Ro 03-8799: Plasma, urine, tumour and normal brain pharmacokinetics. *Br J Radiol* 1986; 59:107-16.
63. Twentyman PR, Fox NE, Wright KA, **Workman P**, Broadhurst MJ, Martin JA, Bleehen NM. The in vitro effects and cross-resistance patterns of some novel anthracyclines. *Br J Cancer* 1986; 53:585-94.
64. Walton MI, **Workman P**. Reversed-phase high-performance liquid chromatography method for the simultaneous estimation of the 2-nitroimidazole benzimidazole and its amine metabolite in biological materials. *J Chromatogr* 1986; 375:190.
65. Watson JV, **Workman P**. Estimating the kinetic parameters for enzymatic drug metabolism in the whole animal. *Biochem Pharmacol* 1986; 35:145-9.
66. **Workman P**. Chemosensitization of lomustine by misonidazole, benzimidazole, and RSU 1069. *Cancer Treat Rep* 70:1139-40.
67. **Workman P**, Morgan JE, Talbot K, Wright KA, Donaldson JA, Twentyman PR. CB 1954 revisited. II. Toxicity and antitumour activity. *Cancer Chemother Pharmacol* 1986; 16:9-14.
68. **Workman P**, Walton MI, Lee FYF. Benzimidazole: Nitroreduction and inhibition of cytochrome P-450 in chemosensitization of tumour response to cytotoxic drugs. *Biochem Pharmacol* 1986; 35:117-9.
69. **Workman P**, White RAS, Talbot K. CB 1954 revisited. I. Disposition kinetics and metabolism. *Cancer Chemother Pharmacol* 1986; 16:1-8.

1987

70. Dive C, **Workman P**, Watson JV. Improved methodology for intracellular enzyme reaction and inhibition kinetics by flow cytometry. *Cytometry* 1987; 8:552-61.
71. Dive C, **Workman P**, Watson JV. Novel dynamic flow cytological determination of intracellular esterase inhibition by BCNU and related isocyanates. *Biochem Pharmacol* 1987; 36:3731-8.

72. Lee FYF, **Workman P**, Cheeseman KH. Misonidazole and benznidazole inhibit hydroxylation of CCNU by mouse liver cytochrome P-450 in vitro. *Biochem Pharmacol* 1987; 36:1349-55.
73. Walton MI, Bleehen NM, **Workman P**. Heat-stimulated nitroreductive bioactivation of the 2-nitroimidazole benznidazole in vitro. *Biochem Pharmacol* 1987; 36:2627-32.
74. Walton MI, Bleehen NM, **Workman P**. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole Ro 03-8799 in mice. *Br J Cancer* 1987; 55:469-76.
75. Walton MI, **Workman P**. Nitroimidazole bioreductive metabolism: Quantitation and characterisation of mouse tissue benznidazole nitroreductase in vivo and in vitro. *Biochem Pharmacol* 1987; 36:887-96.
76. Ward R, **Workman P**. Gradient high-performance liquid chromatography method for simultaneous assay of the radiosensitizers etanidazole (SR 2508) and pimonidazole (Ro 03-8799) in biological materials. *J Chromatogr* 1987; 420:223-7.
77. **Workman P**, Oppitz M, Donaldson JA, Lee FYF. High-performance liquid chromatography of chlorambucil analogues. *J Chromatogr* 1987; 422:315-21.

1988

78. Bleehen NM, Walton MI, **Workman P**. The interactions of hyperthermia with hypoxic cell sensitizers. *Recent Results Cancer Res* 1988; 109:136-48.
79. Dive C, Cox H, Watson JV, **Workman P**. Polar fluorescein derivatives as improved substrate probes for flow cytoenzymological assay of cellular esterases. *Mol Cell Probes* 1988; 2:131-45.
80. Dive C, **Workman P**, Watson JV. Inhibition of intracellular esterases by antitumour chloroethylnitrosoureas: Measurement by flow cytometry and correlation with molecular carbamoylation activity. *Biochem Pharmacol* 1988; 37:3987-93.
81. Freedman LS, **Workman P**. When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? *Cancer Chemother Pharmacol* 1988; 22:95-103.
82. Honess DJ, Wasserman TH, **Workman P**, Ward R, Bleehen NM. Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system. *Int J Radiat Oncol Biol Phys* 1988; 15:671-5.
83. Mbidde EK, Selby PJ, Perren TJ, Dearnley D, Whitton A, Ashley S, **Workman P**, Bloom HJG, McElwain TJ. High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. *Br J Cancer* 1988; 58:779-82.
84. Newman HFV, Bleehen NM, Ward R, **Workman P**. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: A new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). *Int J Radiat Oncol Biol Phys* 1988; 15:677-84.
85. Newman HFV, Bleehen NM, Ward R, **Workman P**. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 4508 (etanidazole). *Int J Radiat Oncol Biol Phys* 1988; 15:1073-83.
86. Walton MI, **Workman P**. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. *Cancer Chemother Pharmacol* 1988; 22:275-81.
87. Walton MI, **Workman P**. High-performance liquid chromatography assay for the novel benzotriazine di-N-oxide (SR 4233) and its reduced metabolites in biological material. *J Chromatogr* 1988; 430:429-37.

1989

88. Bleehen NM, Newman HFV, Maughan TS, **Workman P**. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). *Int J Radiat Oncol Biol Phys* 1989; 16:1093-6.
89. Coley HM, Twentyman PR, **Workman P**. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. *Cancer Chemother Pharmacol* 1989; 24:284-90.

90. Coley HM, Twentyman PR, **Workman P**. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin. *Biochemical Pharmacol* 1989; 38:4467-75.
91. Dive C, **Workman P**, Watson JV. Inhibition of cellular esterases by antitumour imidazotetrazines, mitozolomide and temozolomide: Demonstration by flow cytometry and conventional spectrofluorimetry. *Cancer Chemother Pharmacol* 1989; 25:149-55.
92. Maxwell RJ, **Workman P**, Griffiths JR. Demonstration of tumour-selective retention of fluorinated nitroimidazole probes by ¹⁹F magnetic resonance spectroscopy in vivo. *Int J Radiat Oncol Biol Phys* 1989; 16:925-9.
93. Walton MI, Bleehen NM, **Workman P**. Effects of elevated temperature on misonidazole O-demethylation by mouse liver microsomes: Kinetic and stability studies of a model mixed-function oxidase reaction. *Cancer Chemother Pharmacol* 1989; 24:172-6.
94. Walton MI, Bleehen NM, **Workman P**. Stimulation by localised tumour hyperthermia of the reductive bioactivation of the 2-nitroimidazole benzimidazole in mice. *Cancer Res* 1989; 49:2351-5.
95. Walton MI, Bleehen NM, **Workman P**. Effect of localized tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice. *Br J Cancer* 1989; 59:667-73.
96. Walton MI, Wolf CR, **Workman P**. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. *Int J Radiat Oncol Biol Phys* 1989; 16:983-6.
97. **Workman P**. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: A possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination. *Int J Radiat Oncol Biol Phys* 1989; 16:1011-4.
98. **Workman P**, Ward R, Newman HFV, Maughan TS, Bleehen NM. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment. *Int J Radiat Oncol Biol Phys* 1989; 17:177-81.

1990

99. Binger M, **Workman P**. Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent EO9 in biological specimens. *J Chromatogr* 1990; 532:321-36.
100. Coley HM, Twentyman PR, **Workman P**. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. *Eur J Cancer* 1990; 26:665-7.
101. Dive C, Watson JV, **Workman P**. Multiparametric analysis of cell membrane permeability by two colour flow cytometry with complementary fluorescent probes. *Cytometry* 1990; 11:244-52.
102. Hartman NG, Patterson LH, **Workman P**, Suarato A, Angelucci F. Doxorubicin-3'-NH-oestrone-17-oxime-ethyl-carbonyl, a doxorubicin-oestrone conjugate that does not redox cycle in rat liver microsomes. *Biochem Pharmacol* 1990; 40:1164-7.
103. Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, **Workman P**, Harris AL, Hickson ID. Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. *Cancer Res* 1990; 50:4692-7.
104. Maughan TS, Newman HFV, Bleehen NM, **Workman P**. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508). *Int J Radiat Oncol Biol Phys* 1990; 18:1151-6.
105. Walton MI, **Workman P**. Enzymology of the reductive bioactivation of SR-4233: A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. *Biochem Pharmacol* 1990; 39:1735-42.
106. **Workman P**, Walton MI, Powis G, Schlager JJ. DT-diaphorase: Questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? *Br J Cancer* 1989; 60:800-2.

1991

107. Binger M, **Workman P**. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin α -(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). *Cancer Chemother Pharmacol* 1991; 29:37-47.
108. Bleehen NM, Maughan TS, **Workman P**, Newman HFV, Stenning S, Ward R. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: A toxicity and pharmacokinetic study. *Radiother Oncol* 1991; 20 Suppl 1:137-42.
109. Coley HM, **Workman P**, Twentyman PR. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. *Br J Cancer* 1991;63:351-7.
110. Dive C, Watson JV, **Workman P**. Multiparametric flow cytometry of the modulation of tumour cell membrane permeability by developmental ether lipid SRI 62-834 in EMT6 mouse mammary tumour and HL-60 human promyelocytic leukemia cells. *Cancer Res* 1991; 51:799-806.
111. Walton MI, Smith PJ, **Workman P**. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. *Cancer Commun* 1991; 3:199-206.
112. **Workman P**, Donaldson JA, Lohmeyer M. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells. *Biochem Pharmacol* 1991; 41:319-22.
113. **Workman P**, Newman HFV, Bleehen NM, Ward R, Smithen CE. Lack of stereoselectivity in the pharmacokinetics and metabolism of Ro 03-8799 (pimonidazole) in man. *Cancer Chemother Pharmacol* 1991; 28:118-22.

1992

114. Bailey SM, Suggett N, Walton MI, **Workman P**. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones. *Cancer Chemother Pharmacol* 1992; 22:649-53.
115. Coley HM, Twentyman PR, **Workman P**. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance. *Anticancer Drug Des* 1992; 7:471-81.
116. Cummings J, Allan L, Willmot N, Riley R, **Workman P**, Smyth JF. The enzymology of doxorubicin quinone reduction in tumour tissue. *Biochemical Pharmacology*. 1992; 44:2175-83.
117. Huxham IM, Gaze MN, **Workman P**, Mairs RJ. The use of parallel EEL spectral imaging and elemental mapping in the rapid assessment of anti-cancer drug localization. *J Microsc* 1992; 166:367-80.
118. Lohmeyer M, **Workman P**. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: Further evidence for a non-receptor mediated mechanism of action. *Biochem Pharmacol* 1992; 44:819-23.
119. Maughan TS, **Workman P**, Dennis I, Ward R, Bleehen NM. Tumour concentrations of flavone acetic acid (FAA) in human melanoma. *Br J Cancer* 1992; 66:579-82.
120. Ramsay JRS, Bleehen NM, Dennis I, **Workman P**, Ward R, Falk SJ, Bedford P, Wooton R, Nethersell ABW. Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer. *Int J Radiat Oncol Biol Phys* 1992; 22:721-5.
121. Riley R, **Workman P**. Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H:(quinone-acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. *Biochem Pharmacol* 1992; 43:167-74.
122. Walton MI, Bibby MA, Double JA, Plumb JA, **Workman P**. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. *Eur J Cancer* 1992; 28A:1597-600.
123. Walton MI, Suggett N, **Workman P**. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. *Int J Radiat Oncol Biol Phys* 1992; 22:643-7.
124. Walton MI, Wolf CR, **Workman P**. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cell

cytotoxin 3-amino 1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. *Biochem Pharmacol* 1992; 44:251-9.

125. **Workman P**, Binger M, Kooistra KL. Pharmacokinetics, distribution and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. *Int J Radiat Oncol Biol Phys* 1992; 22:713-6.

1993

126. Brunton VG, **Workman P**. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. *Br J Cancer* 1993; 67:989-95.
127. Coley HM, Amos WB, Twentyman PR, **Workman P**. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. *Br J Cancer* 1993; 67:1316-23.
128. Coley HM, Twentyman PR, **Workman P**. The efflux of anthracyclines in multidrug-resistant cell lines. *Biochem Pharmacol* 1993; 46:1317-26.
129. de Vries EGE, Gietama JA, **Workman P**, Scott JE, Crawshaw A, Dobbs HJ, Dennis I, Mulder NH, Sleijfer DT, Willemse PHB. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. *Br J Cancer* 1993; 68:641-4.
130. Dennis IF, Ramsay JRS, **Workman P**, Bleehen NM. Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase I study in patients with advanced gastrointestinal cancer. *Cancer Chemother Pharmacol* 1993; 32:67-72.
131. Dive C, **Workman P**, Watson JV. Can flow cytometry be applied to measure membrane-bound enzyme kinetics? Assessment by analysis of γ -glutamyltranspeptidase activity. *Biochem Pharmacol* 1993; 46:643-50.
132. Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar REC, Fiebig HH, Double JA, Hornstra HW, Pinedo HM, **Workman P**, Schwartzmann G. EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. *Eur J Cancer* 1993; 29A:897-906.
133. Lohmeyer M, **Workman P**. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-O-Me. *Biochem Pharmacol* 1993; 45:77-86.
134. Riley RJ, Hemingway SA, Graham MA, **Workman P**. Initial characterisation of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4 di-N-oxide (tirapazamine, SR 4233, WIN 59075). *Biochem Pharmacol* 1993; 45:1065-77.
135. Walton MI, **Workman P**. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. *J Pharmacol Exp Ther* 1993; 265:938-47.

1994

136. Brunton VG, Carlin S, **Workman P**. Alterations in the EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor. *Anticancer Drug Des* 1994; 9:311-29.
137. Brunton VG, Lear MJ, Robins DJ, Williamson S, **Workman P**. Synthesis and antiproliferative activity of tyrophostins containing heteroaromatic moieties. *Anticancer Drug Des* 1994; 9:291-309.
138. Fitzsimmons SA, Lewis AD, Riley RJ, **Workman P**. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine; WIN 59075; SR 4233) to a DNA-damaging species: A direct role for NADPH:cytochrome P450 reductase. *Carcinogenesis* 1994; 15:1503-10.
139. Huxham IM, Barlow AL, Lewis AD, Plumb JA, Mairs RJ, Gaze MN, **Workman P**. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and-resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. *Int J Cancer* 1994; 59:94-102.
140. Lohmeyer M, McNaughton L, Hunt SP, **Workman P**. Stimulation of intracellular free calcium increases by platelet-activating factor in HT29 colon carcinoma cells: Spectrofluorimetric and preliminary spatio-temporal analysis using confocal laser scanning fluorescence imaging microscopy. *Biochem Pharmacol* 1994; 47:975-85.

141. Moody CJ, O'Sullivan N, Stratford IJ, Stephens MA, **Workman P**, Bailey SM, Lewis AD. Cyclopropamitosenes: Novel bioreductive anticancer agents - Mechanism of action and enzymic reduction. *Anticancer Drugs* 1994; 5:367-72.
142. Plumb JA, Gerritsen M, Milroy R, Thomson P, **Workman P**. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor lines. *Int J Radiat Oncol Biol Phys* 1994; 29:295-9.
143. Plumb JA, Gerritsen M, **Workman P**. DT-diaphorase protects cells from the hypoxic cytotoxicity of EO9. *Br J Cancer* 1994; 70:1136-43.
144. Plumb JA, **Workman P**. Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. *Int J Cancer* 1994; 56:134-9.
145. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, **Workman P**. Direct measurement of pO₂ distribution and bioreductive enzymes in human malignant brain tumors. *Int J Radiat Oncol Biol Phys* 1994; 29:427-31.

1995

146. Aboagye EO, Graham MA, Lewis AD, **Workman P**, Kelson AB, Tracy M. Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-4554) in Balb/c mouse plasma. *J Chromatogr B Biomed Appl* 1995; 672:125-32.
147. Aboagye EO, Lewis AD, Johnson A, **Workman P**, Tracy M, Huxham IM. The novel fluorinated hypoxia probe SR-4554: Reductive metabolism and semi-quantitative localisation in human ovarian cancer multicellular spheroids as measured by electron loss spectroscopic analysis. *Br J Cancer* 1995; 72:312-8.
148. Chen S, Knox RJ, Lewis AD, Friedlos F, **Workman P**, Deng PSK, Fung M, Ebenstein D, Wu K, Tsai T. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: Study involving mouse, rat, human and mouse-rat chimeric enzymes. *Mol Pharmacol* 1995; 47:934-9.
149. Lohmeyer M, **Workman P**. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro antitumour activity of ether lipids. *Br J Cancer* 1995; 72:277-86.
150. Robin HJ, Senan S, **Workman P**, Graham MA. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatographic assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically-guided dose escalation. *Cancer Chemother Pharmacol* 1995; 36:266-70.

1996

151. Aboagye EO, Lewis AD, Graham MA, Tracy M, Kelson AB, Ryan K, **Workman P**. Pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed fluorinated 2-nitroimidazole probe SR-4554 for the detection of hypoxia by magnetic resonance spectroscopy. *Anticancer Drug Des* 1996; 11:231-42.
152. Brunton VG, Kelland LR, Lear MJ, Montgomery GJ, Robertson JH, Robins DJ, Queen J, **Workman P**. Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors. *Anticancer Drug Des* 1996; 11:265-95.
153. Brunton VG, Lear MJ, McKeown P, Robins DJ, **Workman P**. Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties. *Anticancer Drug Des* 1996; 11:463-83.
154. Fitzsimmons SA, **Workman P**, Grever M, Paull K, Camelier R, Lewis AD. Reductase expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9. *J Natl Cancer Inst* 1996; 88:259-69.
155. Henderson ND, Plumb JA, Robins DJ, **Workman P**. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides. *Anticancer Drug Des* 1996; 11:421-38.
156. McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, **Workman P**, Graham MA. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. *Br J Cancer* 1996; 74:1714-6.
- 157.

1997

158. Aboagye EO, Lewis AD, Tracy M, **Workman P**. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). *Biochem Pharmacol* 1997; 54:1217-24.
159. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, **Workman P**. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. *Cancer Res* 1997; 57:3314-8.
160. Bailey SM, Wyatt MD, Friedlos F, Hartley JA, Knox RJ, Lewis AD, **Workman P**. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. *Br J Cancer* 1997; 76:1596-603.
161. Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, McAully G, Hill R, Kerr DJ, **Workman P**, Wakelam MJ. Inhibition of phospholipid signaling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin. *Biochim Biophys Acta* 1997; 1362:29-38.
162. Graham MA, Senan S, Robin Jnr H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, **Workman P**. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation. *Cancer Chemother Pharmacol* 1997; 40:1-10.
163. Senan S, Rampling R, Graham MA, Wilson P, Robin Jr H, Eckardt N, Lawson N, McDonald A, von Roeming R, **Workman P**, Kaye SB. Phase I and pharmacokinetic study of single agent tirapazamine (SR 4233) administered 3-weekly. *Clin Cancer Res* 1997; 3:31-8.

1998

164. Aboagye EO, Kelson AB, Tracy M, **Workman P**, Neidle S, Sausville E, Powis G, Andoh T. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. *Anticancer Drug Des* 1998;703-30.
165. Aboagye EO, Maxwell RJ, Horsman MR, Lewis AD, **Workman P**, Tracy M, Griffiths JR. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. *Br J Cancer* 1998; 77:65-70.
166. Bailey SM, Lewis AD, Knox RJ, Patterson LH, Fisher GR, **Workman P**. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: A detailed kinetic study and analysis of metabolites. *Biochem Pharmacol* 1998; 56:613-21.
167. Brunton VG, Steele G, Lewis AD, **Workman P**. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: Evidence against the involvement of c-Src or DT-diaphorase. *Cancer Chemother Pharmacol* 1998; 41:417-22.

1999

168. Kelland LR, Sharp SY, Rogers PM, Myers TG, **Workman P**. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. *J Natl Cancer Inst* 1999; 91:1940-9.

2000

169. Clarke PA, Hostein I, Banerji U, Di Stefano F, Maloney A, Walton M, Judson I, **Workman P**. Gene expression profiling of human colon adenocarcinoma cells following inhibition of signal transduction by 17-allylamino-17-demethoxy-geldanamycin, an inhibitor of the Hsp90 molecular chaperone. *Oncogene* 2000; 19:4125-33.

170. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs SM, **Workman P**. Establishment of an isogenic human colon tumour model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. *Mol Pharmacol* 2000; 58:1146-55.

2001

171. Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, **Workman P**. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. *Biochem Pharmacol* 2001; 62:461-8.
172. Hostein I, Robertson D, Di Stefano F, **Workman P**, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. *Cancer Res* 2001; 61:4003-9.
173. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, **Workman P**, Johnston SRD. Preclinical antitumor activity and pharmacodynamic studies with the farnesylprotein transferase inhibitor R115777 in human breast cancer. *Clin Cancer Res* 2001; 7:3544-50.
174. Ross PJ, George ML, Cunningham D, Di Stefano F, Andreyev HJN, **Workman P**, Clarke PA. Inhibition of kirsten-ras expression in human colorectal cancer using rationally selected kirsten-ras antisense oligonucleotides. *Mol Cancer Ther* 2001; 1:29-41.
175. Seddon BM, Honess DJ, Vojnovic B, Tozer GM, **Workman P**. Measurement of tumor oxygenation: In vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the P22 tumor. *Radiat Res* 2001; 155:837-46.
176. Smith V, Raynaud FI, **Workman P**, Kelland LR. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. *Mol Pharmacol* 2001; 60:885-93.
177. Turlais F, Hardcastle A, Rowlands MG, Newbatt Y, Bannister A, Kouzarides T, **Workman P**, Aherne GW. High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate). *Anal Biochem* 2001; 298:62-8.

2002

178. Liu D, Hutchinson OC, Osman S, Price P, **Workman P**, Aboagye EO. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. *Br J Cancer* 2002; 87:783-9.
179. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, Millison SH, Clarke PA, Naaby-Hansen S, Stein R, Cramer R, Mollapour M, **Workman P**, Piper PW, Pearl LH, Prodromou C. Activation of the ATPase activity of Hsp90 by Aha1, a novel stress-regulated co-chaperone. *Mol Cell* 2002; 10:1307-18.
180. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, **Workman P**. Validation of the fluorinated 2-nitroimidazole-SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. *Clin Cancer Res* 2002; 8:2323-35.
181. Smith V, Hobbs S, Court W, Eccles S, **Workman P**, Kelland LR. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. *Anticancer Res* 2002; 22:1993-9.
182. Smith V, Rowlands MG, Barrie E, **Workman P**, Kelland LR. Establishment and characterization of acquired resistance to the farnesyl protein transferase (FTase) inhibitor R115777 in a human colon cancer cell line. *Clin Cancer Res* 2002; 8:2002-9.

2003

183. Asad Y, Cropp G, Adams A, O'Donnell A, Raynaud F, Judson I, **Workman P**. Validation of a liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial. *J Chromatogr B* 2003; 785:175-86.

184. Barrie SE, Eno-Amooquaye E, Hardcastle A, Platt G, Richards G, Bedford D, **Workman P**, Aherne W, Mitnacht S, Garrett MD. High throughput screening for the identification of small molecule inhibitors of retinoblastoma protein phosphorylation in cells. *Anal Biochem* 2003; 320:66-74.
185. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, **Workman P**, Ronen SM. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. *J Natl Cancer Inst* 2003; 95:1624-33.
186. Clarke PA, George ML, Easdale S, Cunningham D, Swift I, Hill ME, Tait DM, **Workman P**. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. *Cancer Res* 2003; 63:6855-63.
187. Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, Brady F, Bouchier-Hayes L, Martin SJ, **Workman P**, Price P, Aboagye EO. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. *Br J Cancer* 2003; 89:1327-33.
188. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, **Workman P**. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. *Clin Cancer Res* 2003; 9:5101-12.

2004

189. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, **Workman P**, Price PM, Aboagye EO. In vivo evaluation of [F-18] fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. *Br J Cancer* 2004; 90:2232-42.
190. Clarke PA, Pestell KE, Di Stefano F, **Workman P**, Walton MI. Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: Contrasting role for p53 induction and apoptosis in vivo. *Br J Cancer* 2004; 91:1614-23.
191. Griffiths G, Koh MY, Brunton V, Cawthorne C, Reeves N, Greaves M, Tilby M, Pearson D, Ottley C, **Workman P**, Frame M, Dive C. Expression of kinase defective mutants of c-Src in human metastatic colon decreases Bcl-x-L and increases Oxaliplatin- and Fas-induced apoptosis. *J Biol Chem* 2004; 279:46113-21.
192. Kote-Jarai Z, Williams R, Cattini N, Copeland M, Giddings I, Wooster R, te Poele R, **Workman P**, Gusterson B, Peacock J, Gui G, Campbell C, Eeles R. Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. *Clin Cancer Res* 2004; 10:958-63.
193. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, **Workman P**. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. *Mol Cancer Ther* 2004; 3:353-62.
194. Renshaw J, Orr RM, Walton MI, te Poele R, Williams RD, Wancewicz EV, Monia BP, **Workman P**, Pritchard-Jones K. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. *Mol Cancer Ther* 2004; 3:1467-83.
195. Rowlands MG, Newbatt YM, Prodromou C, Pearl L, **Workman P**, Aherne W. High throughput screening assay for inhibitors of heat shock protein 90 ATPase activity. *Anal Biochem* 2004; 327:176-83.
196. Smith NF, Hayes A, Nutley BP, Raynaud FI, **Workman P**. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. *Cancer Chemother Pharmacol* 2004; 54:475-86.
197. Sun CB, Newbatt Y, Douglas L, **Workman P**, Aherne W, Linardopoulos S. High-throughput screening assay for identification of small molecule inhibitors of Aurora 2/STK15 kinase. *J Biomol Screen* 2004; 9:391-7.
198. Whittaker SR, Walton MI, Garrett MD, **Workman P**. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma phosphorylation, causes loss of cyclin D1 and activates the mitogen-activated protein kinase pathway. *Cancer Res* 2004; 64:262-72.
199. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, **Workman P**, Hubbard

RE. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. *Chem Biol* 2004;11:775-85.

2005

200. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, **Workman P**, Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies. *J Clin Oncol* 2005; 23:4152-61.
201. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, **Workman P**. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. *Clin Cancer Res* 2005; 11:7023-32.
202. Belouèche-Babari M, Jackson LE, Al-Saffar NMS, **Workman P**, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of MAPK signalling inhibition. *Cancer Res* 2005; 65:3356-63.
203. Brough PA, Barril X, Beswick M, Dymock BW, Drysdale MJ, Wright L, Grant K, Massey A, Surgenor A, **Workman P**. 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. *Bioorg Med Chem Lett* 2005; 15:5197-201.
204. Chau NM, Rogers P, Aherne W, Carroll V, Collins I, McDonald E, **Workman P**, Ashcroft M. Identification of novel small molecule inhibitors of HIF-1 that differentially block HIF-1 activity and HIF-1 α induction in response to hypoxic stress and growth factors. *Cancer Res* 2005; 65:4918-28.
205. Cheung KMJ, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aherne GW, McDonald E, **Workman P**. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. *Bioorg Med Chem Lett* 2005; 15:3338-43.
206. da Rocha Dias S, Light Y, Friedlos F, Springer C, **Workman P**, Marais R. Oncogenic B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-AAG. *Cancer Res* 2005; 65:10686-91.
207. Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, **Workman P**, Wright L, Drysdale MJ. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. *J Med Chem* 2005; 48:4212-5.
208. Hardcastle A, Boxall K, Richards J, Tomlin P, Sharp S, Clarke P, **Workman P**, Aherne W. Solid phase immunoassays in mechanism-based drug discovery: Their application in the development of inhibitors of the molecular chaperone heat-shock protein 90 (Hsp90). *Assay Drug Dev Technol* 2005; 3:273-85.
209. Nutley BP, Hayes A, Griffin R, Smith NF, Kelland LR, Brunton L, Golding B, Smith G, Martin N, **Workman P**, Raynaud F. Preclinical pharmacokinetics, metabolism and radiosensitisation effect of a novel DNA-PK inhibitor NU7026. *Br J Cancer* 2005; 93:1011-8.
210. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, **Workman P**. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. *Mol Cancer Ther* 2005; 4:125-39.
211. O'Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, **Workman P**, Hannah A, Judson I. A phase I study of the angiogenesis inhibitor SU5416, in solid tumours incorporating dynamic contrast MR pharmacodynamic endpoints. *Br J Cancer* 2005; 93:876-83.
212. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, **Workman P**. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin dependent kinase inhibitors olomoucine, bohemine and CYC202. *Clin Cancer Res* 2005; 11:4875-88.
213. Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynaud F, Rogers P, Bavetsias V, Gorsuch S, Jarman M, Bannister A, Kouzarides T, McDonald E, **Workman P**, Aherne GW. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. *Mol Cancer Ther* 2005; 4:1521-32.

214. Walton MI, Wilson SC, Hardcastle IR, Mirza AR, **Workman P**. An evaluation of the ability of pifithrin- α and - β to inhibit p53 function in two wild-type p53 human tumour cell lines. *Mol Cancer Ther* 2005; 4:1369-77.
215. Wood N, Gibbs DD, Jackman AL, Henley A, **Workman P**, Raynaud F. Validation of a high-performance liquid chromatography tandem mass spectrometry assay for the quantitation of BCG945 and BCG638 in mouse plasma. *J Chromatogr B* 2005; 824:181-8.

2006

216. Al-Saffar NMS, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, **Workman P**, Lacal JC, Judson IR, Chung YL. Non-invasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. *Cancer Res* 2006; 66:427-34.
217. Atrash B, Cooper TS, Sheldrake P, **Workman P**, McDonald E. Development of synthetic routes to macrocyclic compounds based on the HSP90 inhibitor radicicol. *Tetrahedron Lett* 2006; 47:2237-40.
218. Barril X, Beswick M, Collier A, Drysdale MJ, Dymock BW, Fink A, Grant K, Jordan AM, Massey A, Surgenor A, Wayne J, **Workman P**, Wright L. 4-Amino derivatives of the pyrazole-based Hsp90 inhibitor CCT018159. *Bioorg Med Chem Lett* 2006; 16:2543-8.
219. Belouèche-Babari M, Jackson LE, Al-Saffar NMS, Eccles SA, Raynaud FI, **Workman P**. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signalling in human breast cancer cells. *Mol Cancer Ther* 2006; 5:187-96.
220. Burns S, Travers J, Collins I, Rowlands MG, Newbatt Y, Thompson N, Garrett M, **Workman P**, Aherne W. Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreenT high-throughput screen. *J Biomol Screen* 2006; 11:822-7.
221. Collins I, Caldwell J, Fonseca T, Donald A, Bavetsias V, Hunter LJK, Garrett MD, Rowlands MG, Aherne GW, Davies TG, Berdini V, Woodhead SJ, Davis D, Seavers LCA, Wyatt PG, **Workman P**, McDonald E. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. *Bioorg Med Chem* 2006; 14:1255-73.
222. Cooper TS, Atrash B, Sheldrake P, **Workman P**, McDonald E. Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis. *Tetrahedron Lett* 2006; 47:2241-3.
223. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, **Workman P**, Waterfield M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110 α inhibitors. *Bioorg Med Chem* 2006; 14:6847-58.
224. Honma M, Stubbs M, Collins I, **Workman P**, Aherne W, Watt FM. Identification of novel keratinocyte differentiation modulating compounds by high-throughput screening. *J Biomol Screen* 2006; 11:977-84.
225. Howes R, Barril X, Dymock BW, Grant K, Northfield CJ, Robertson A, Surgenor A, Wayne J, Wright L, James K, Matthews T, Cheung KM, McDonald E, **Workman P**, Drysdale MJ. A fluorescence polarization assay for inhibitors of Hsp90. *Anal Biochem* 2006; 350:202-13.
226. Knowles HJ, te Poele RH, **Workman P**, Harris AL. Niacin induces PPAR gamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. *Biochem Pharmacol* 2006; 71:646-56.
227. Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, Pillai R, He Q, Atadja P, Lam EW, **Workman P**, Vigushin DM, Aboagye EO. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. *Cancer Res* 2006; 66:7621-9.
228. Moreno-Farre J, Asad Y, Pacey S, **Workman P**, Raynaud FI. Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma. *Rapid Commun Mass Spectrom* 2006; 20:2845-50.
229. Moreno-Farre J, **Workman P**, Raynaud FI. Analysis of potential drug-drug interactions for anticancer agents in human liver microsomes by high throughput liquid chromatography/mass spectrometry assay. *Recent Advances and Research Updates* 2006; 7:224.

230. Newbatt Y, Burns S, Hayward R, Whittaker S, Kirk R, Marshall C, Springer C, Marais R, McDonald E, **Workman P**, Aherne W. Identification of inhibitors of the kinase activity of oncogenic V600E BRAF kinase in an enzyme cascade high throughput screen. *J Biomol Screen* 2006; 11:145-54.
231. Proisy N, Sharp SY, Boxall K, Connelly S, Rose SM, Prodromou C, Slawin AM, Pearl LH, **Workman P**, Moody CJ. Inhibition of Hsp90 with synthetic macrolactones: Synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. *Chem Biol* 2006; 13:1203-15.
232. Sain N, Krishnan B, Ormerod MG, De rienzo A, Liu WM, Kaye SB, **Workman P**, Jackman AL. Potentiation of paclitaxel activity by the HSP inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. *Mol Cancer Ther* 2006; 5:1197-208.
233. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, **Workman P**, Eccles S. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. *Mol Cancer Ther* 2006; 5:522-32.
234. Smith NF, Hayes A, James K, Nutley BP, McDonald E, Henley A, Dymock B, Drysdale MJ, Raynaud FI, **Workman P**. Preclinical pharmacokinetics and metabolism of a novel diarylpyrazole resorcinol series of Heat Shock Protein 90 inhibitors. *Mol Cancer Ther* 2006; 5:1628-37.

2007

235. Bavetsias V, Sun C, Bouloc N, Reynisson J, **Workman P**, Linardopoulos S. Hit generation and exploration: Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. *Bioorg Med Chem Lett* 2007; 17:6567-71.
236. Benson C, White J, de Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, **Workman P**, Kaye S, Cassidy J, Gianella-Boradelli A, Judson I, Twelves C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. *Br J Cancer* 2007; 96:29-37.
237. Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, Martins V, Wilsher NE, Raynaud FI, Valenti M, Eccles S, te Poele R, **Workman P**, Aboagye EO, Linardopoulos S. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. *Mol Cancer Ther* 2007; 6:3147-57.
238. Davenport EL, Moore HE, Dunlop AS, Sharp SY, **Workman P**, Morgan GJ, Davies FE. Heat shock protein inhibition is associated with activation of the unfolded protein response (UPR) pathway in myeloma plasma cells. *Blood* 2007; 110:2641-9.
239. Davies TG, Verdonk ML, Graham B, Saalau-Bethell S, Hamlett CC, McHardy T, Collins I, Garrett MD, **Workman P**, Woodhead SJ, Jhoti H, Barford D. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. *J Mol Biol* 2007; 367:882-94.
240. Gowan SM, Hardcastle A, Hallsworth AE, Valenti MR, Hunter LJ, De Haven Brandon AK, Garrett MD, Raynaud F, **Workman P**, Aherne W, Eccles SA. Application of MesoScale technology for the measurement of phosphoproteins in human tumour xenografts. *Assay Drug Dev Technol* 2007; 5:391-401.
241. Hardcastle A, Tomlin P, Norris C, Richards J, Cordwell M, Boxall K, Rowlands M, Jones K, Collins I, McDonald E, **Workman P**, Aherne W. A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone HSP90 and modulators of cellular acetylation. *Mol Cancer Ther* 2007; 6:1112-22.
242. Hayakawa H, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, **Workman P**, Waterfield M, Parker P. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110 α inhibitors. *Bioorg Med Chem Lett* 2007; 17:2438-42.
243. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, **Workman P**, Waterfield M. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110 α inhibitors. *Bioorg Med Chem* 2007; 15:5837-44.

244. Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Koda M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, **Workman P**. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110 α inhibitors. *Bioorg Med Chem* 2007; 15:403-12.
245. Hockley SL, Arlt VM, Brewer D, te Poele R, **Workman P**, Giddings I, Phillips DH. AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. *Chem Res Toxicol* 2007; 20:1797-810.
246. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, de Billy E, Salmons J, Walton M, Burlingame A, Waterfield M, **Workman P**. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. *Cancer Res* 2007; 67:3239-53.
247. McErlean CS, Proisy N, Davic CJ, Boland NA, Sharp SY, Boxall K, Slawin AM, **Workman P**, Moody CJ. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin. *Org Biomol Chem* 2007; 5:531-46.
248. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa H, Koizumi T, Ohishi T, Patel S, Saguir N, Parker P, Waterfield M, **Workman P**. Pharmacological characterisation of a potent inhibitor of class 1 phosphatidylinositide 3-kinases. *Cancer Res* 2007; 67:5840-50.
249. Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KMJ, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, **Workman P**. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of HSP90 inhibitors. *Cancer Res* 2007; 67:2206-16.
250. Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G, Matthews TP, Cheung KJ, Kalusa A, James K, Hayes A, Hardcastle A, Dymock B, Brough PA, Barril X, Cansfield JE, Wright L, Surgenor A, Foloppe N, Hubbard RE, Aherne W, Pearl L, Jones K, McDonald E, Raynaud F, Eccles S, Drysdale M, **Workman P**. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. *Mol Cancer Ther* 2007; 6:1198-211.
251. Whittaker SR, te Poele RT, Chan F, Linardopoulos S, Walton MI, Garrett MD, **Workman P**. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. *Cell Cycle* 2007; 6:3114-31.
252. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, **Workman P**, Shipley J. Role of amplification and expression of glypican-5 in rhabdomyosarcoma. *Cancer Res* 2007; Jan 1;67(1):57-65.

2008

253. Banerji U, Affolter A, Judson I, Marais R, **Workman P**. BRAF and NRAS mutations in melanoma: Potential relationships to clinical response to HSP90 inhibitors. *Mol Cancer Ther* 2008; 7:737-9.
254. Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, **Workman P**. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. *Cancer Chemother Pharmacol* 2008; 62:769-78.
255. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall B, Cansfield JE, Cheung KM, Collins I, Davies NGM, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews T, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, **Workman P**, Wright L. 4,5-Diaryl isoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. *J Med Chem* 2008; 51:196-218.

256. Caldwell JJ, Davies TG, Donald A, McHardy T, Rowlands MG, Aherne GW, Hunter LK, Taylor K, Ruddle RR, Raynaud FI, Verdonk M, **Workman P**, Garrett MD, Collins I. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. *J Med Chem* 2008; 51:2147-57.
257. Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, **Workman P**, Leach MO, Belouèche-Babari M. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. *Neoplasia* 2008; 10:303-13.
258. de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, **Workman P**, Kaye S, Rowinsky EC, Aherne W, Atadja P, Scott JW, Patnaik A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumours. *Clin Cancer Res* 2008; 14:6663-73.
259. Eccles SA, Massey A, Raynaud F, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, **Workman P**. NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis and metastasis. *Cancer Res* 2008; 68:2850-60.
260. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GJ, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJA, Wan NC, Weismann C, **Workman P**, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ. The identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. *J Med Chem* 2008; 51:5522-32.
261. Holmes JL, Sharp SY, Hobbs S, **Workman P**. Silencing of HSP90 co-chaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). *Cancer Res* 2008; 68:1188-97.
262. Jefferies HB, Cooke FT, Jat P, Boucheron C, Koizumi T, Hayakawa M, Kaizawa H, Ohishi T, **Workman P**, Waterfield MD, Parker PJ. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. *EMBO Rep* 2008; 9:164-70.
263. Leyton J, Smith G, Lees M, Perumal M, Nguyen Q, Aigbirhio FI, Golovko O, He Q, **Workman P**, Aboagye EO. Non-invasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. *Mol Cancer Ther* 2008; 7:3112-21.
264. Powers MV, Clarke PA, **Workman P**. Dual targeting HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. *Cancer Cell* 2008; 14:250-62.
265. Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K, Jones K, Linardopoulos S, **Workman P**, Aherne W, Lord CJ, Ashworth A. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. *Oncogene* 2008; 27:1036-44.
266. Vaughan CK, Mollapour M, Smith J, Truman A, Hu B, Good VM, Panaretou B, Neckers L, Clarke PA, **Workman P**, Piper PW, Prodromou C, Pearl LH. Hsp90-dependent activation of protein kinases is regulated by chaperon-targeted dephosphorylation of Cdc37. *Mol Cell* 2008; 31:886-95.

2009

267. Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, Lopez Lazaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, **Workman P**, de Bono JS, Verweij J. Phase I safety, pharmacokinetic and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumours. *Mol Cancer Ther* 2009; 8:1430-7.
268. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Sharp SY, Reis-Filho JS, Stavale JN, Al-Sarraj S, Reis RM, Vassal G, Perason ADJ, Hargrave D, Ellison

- DW, **Workman P**, Jones C. EGFRvIII deletion mutations in paediatric high grade glioma and response to targeted therapy in paediatric glioma cell lines. *Clin Cancer Res* 2009; 15:5753-61.
269. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, **Workman P**, Sheer D, Reis RM, Pearson ADJ, Hargrave D, Jones C. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. *PLoS ONE* 2009; 4:e5209.
270. Brough PA, Barril X, Borgognoni J, Chene P, Davies NGM, Davis B, Drysdale MJ, Dymock B, Eccles SA, Garcia-Echeverria C, Fromont C, Hayes A, Hubbard RE, Jordan AM, Jensen MR, Massey A, Merrett A, Padfield A, Parsons R, Radimerski T, Raynaud FI, Robertson A, Roughley SD, Schoepfer J, Simmonite H, Sharp SY, Surgenor A, Valenti M, Walls S, Webb P, Wood M, **Workman P**, Wright L. Combining hit identification strategies: Fragment-based and *in silico* approaches to orally active 2-aminothieno[2,3-*d*]pyrimidine inhibitors of the Hsp90 molecular chaperone. *J Med Chem* 2009; 52:4794-809.
271. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, **Workman P**. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cell lines. *Cancer Res* 2009; 69:1966-75.
272. Gorsuch S, Bavetsias V, Rowlands MG, Aherne GW, **Workman P**, Jarman M, McDonald E. Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs). *Bioorg Med Chem* 2009; 17:467-74.
273. Guillard S, Clarke PA, te Poele R, Mohri Z, Bjerke L, Valenti M, Raynaud F, Eccles SA, **Workman P**. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. *Cell Cycle* 2009; 8:443-53.
274. Lee CP, Payne GS, Oregioni A, Ruddle R, Tan S, Raynaud FI, Eaton D, Campbell MJ, Cross K, Halbert G, Tracy M, McNamara J, Seddon B, Leach MO, **Workman P**, Judson I. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. *Br J Cancer* 2009; 101:1860-8.
275. Prodromou C, Nuttall JM, Millson SH, Roe MS, Pearl L, Tiow-Suan S, Tan D, **Workman P**, Piper PW. The structural basis of the radicicol resistant displayed by a fungal Hsp90. *ACS Chem Biol* 2009; 4:289-97.
276. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, de Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, **Workman P**. Biological properties of potent inhibitors of Class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC-0941. *Mol Cancer Ther* 2009; 8:1725-38.
277. Reynisson J, Court W, O'Neill C, Day J, Patterson L, McDonald E, **Workman P**, Katan M, Eccles S. The identification of novel PLC- γ inhibitors using virtual high throughput screening. *Bioorg Med Chem* 2009; 17:3169-76.
278. Rogers SJ, Box C, Chambers P, Barbachano Y, Nutting CM, Rhys-Evans P, **Workman P**, Harrington KJ, Eccles SA. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. *J Pathol* 2009; 218:122-30.
279. Smith JR, Clarke PA, de Billy E, **Workman P**. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HPS90 inhibitors. *Oncogene* 2009; 28:157-69.

2010

280. Al-Saffar NMS, Jackson LE, Raynaud FI, Clarke PA, de Molina AR, Lacal JC, **Workman P**, Leach MO. The PI3K inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. *Cancer Res* 2010;70:5507-17.
281. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI,

- Workman P**, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. *J Med Chem* 2010;22:53:5213-28.
282. Belouèche-Babari, Arunan V, Jackson LE, Perusinghe N, Sharp SY, **Workman P**, Leach MO. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. *Oncotarget* 2010; 1:185-97.
283. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D, Smith EM, Powers MV, Sharp SY, **Workman P**, Morgan GJ, Davies FE. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. *Leukemia* 2010;24:1804-7.
284. Day JE, Sharp SY, Rowlands MG, Aherne W, **Workman P**, Moody CJ. Targeting the Hsp90 chaperone: Synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90. *Chemistry* 2010; 16:2758-63.
285. Day JE, Sharp SY, Rowlands MG, Aherne W, Lewis W, Prodromou C, Roe SM, Pearl LH, **Workman P**, Moody CJ. Inhibition of Hsp90 with resorcylic acid macrolactones. Synthesis and binding studies. *Chemistry* 2010;16:10366-72.
286. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, **Workman P**, McDonald E, Blagg J, Aherne W, Dale T. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. *Cancer Res.* 2010;70:5963-73.
287. Gaspar N, Sharp SY, Eccles S, Gowan S, Popov S, Jones C, Pearson A, Vassal G, **Workman P**. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. *Mol Cancer Ther* 2010; 9:1219-33.
288. Gaspar N, Marshall L, Perryman L, Bax D, Little S, Pereira-Viana M, Sharp S, Vassal G, Pearson A, Reis R, Hargrave D, **Workman P**, Jones C. MGMT-independent temozolomide resistance in paediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. *Cancer Res* 2010;70: 9243-52.
289. Grimshaw KM, Hunter LK, Yap TA, Heaton S, Walton MI, Woodhead S, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, **Workman P**, Garrett MD. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. *Mol Cancer Ther* 2010; 9:1100-10.
290. Hayward G Daniel, Newbatt Y, Pickard L, Byrne E, Mao G, Burns S., Sahota Navdeep K , **Workman P**, Collins Ian, Aherne Wynne, and Fry Andrew M. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated Nek2 kinase. *J Biomol Screen* 2010;15: 918-27.
291. Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, **Workman P**, Eisen T. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. *Invest New Drugs.* 2010. Aug 12. (Epub ahead of print).
292. Rowlands M, McAndrew C, Prodromou C, Pearl L, Kalusa A, Jones K, **Workman P**, Aherne W. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the transcreenerTM ADP assay kit. *J Biomol Screen* 2010; 15: 279-286.

2011

293. Belouèche-Babari M, **Workman P**, Leach MO. Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents. *Cell Cycle.* 2011: 17:2883-93. Epub 2011 Sep 1.
294. Day JE, Sharp SY, Rowlands MG, Aherne W, Hayes A, Raynaud FI, Lewis W, Roe SM, Prodromou C, Pearl LH, **Workman P**, Moody CJ. Targeting the Hsp90 molecular chaperone with novel macrolactams. Synthesis, structural, binding, and cellular studies. *ACS Chem Biol.* 2011; 6: 12:1339-47. doi: 10.1021/cb200196e. Epub 2011 Oct 4.
295. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, **Workman P**, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. *Mol Cancer Ther.* 2011: 11:2115-23. Epub 2011 Sep 1.

296. Large JM, Torr JE, Raynaud FI, Clarke PA, Hayes A, Stefano FD, Urban F, Shuttleworth SJ, Saghir N, Sheldrake P, **Workman P**, McDonald E. Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements. *Bioorg Med Chem* 2011;19: 836-51.
297. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zutterlund A, Arkenau H-T, Moreno-Farre J, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, **Workman P**, Judson I. A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumours. *Clin Cancer Res* 2011;17: 1561-70.
298. Rao S, Welsh L, Cunningham D, te Poele RH, Benson M, Norman A, Saffery C, Giddings I, **Workman P**, Clarke PA. Correlation of overall survival with gene expression profiles in a prospective study of resectable oesophageal cancer. *Clin Colorectal Cancer* 2011; 10:48-56.
299. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, **Workman P**, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. *Sci Transl Med*. 2011; 3: 85:85.
300. Wilson SC, Atrash B, Barlow C, Eccles S, Fischer PM, Hayes A, Kelland L, Jackson W, Jarman M, Mirza A, Moreno J, Nutley BP, Raynaud FI, Sheldrake P, Walton M, Westwood R, Whittaker S, **Workman P**, McDonald E. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. *Bioorg Med Chem*. 2011; 19: 6949-65.
301. Yap TA, Walton MI, Hunter LK, Valenti M, Even P, Martins V, Heaton SI, Henley A, Pickard L, Caldwell JJ, Thompson N, Raynaud FI, Eccles SA, **Workman P**, Collins I, Garrett MD. Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. *Mol Cancer Ther* 2011;10:360-71.

2012

302. Belouèche-Babari M, Arunan V, Troy H, Te Poele RH, Te Fong AC, Jackson LE, Payne GS, Griffiths JR, Judson IR, **Workman P**, Leach MO, Chung YL. Histone Deacetylase Inhibition Increases Levels of Choline Kinase α and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers. *Cancer Res*. 2012; 72:990-1000.
303. Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, **Workman P**, de Bono JS, Gore M, Kaye SB, Banerji U. The association of PI3 kinase signalling and chemo-resistance in advanced ovarian cancer. *Mol Cancer Ther*. 2012; 7:1609-17.
304. Moore AS, Faisal A, de Castro DG, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, **Workman P**, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S. Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. *Leukemia*. 2012;7:1462-70.
305. Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW, Wilson SC, Sheldrake P, McDonald E, Venet M, Soudy C, Elustondo F, Rigoreau L, Blagg J, **Workman P**, Garrett MD, Mitnacht S. Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. *PLoS One*. 2012; 7:e28568 Epub 2012.
306. Zaidi S, McLaughlin M, Bhide SA, Eccles SA, **Workman P**, Nutting CM, Huddart RA, Harrington KJ. The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage. *PLoS One*. 2012;7: e35436. Epub 2012.
307. Rodrigues LM, Chung YL, Al Saffar NM, Sharp SY, Jackson LE, Banerji U, Stubbs M, Leach MO, Griffiths JR, **Workman P**. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEUNT mice monitored by Magnetic Resonance Spectroscopy. *BMC Res Notes*. 2012 May 23;5(1):250. [Epub ahead of print]
308. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, **Workman P**, Thompson NT, Garrett MD.

- AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. *Clin Cancer Res* 2012 18; 3912-23. Epub 2012 Jul 10.
309. Francis NJ, Rowlands M, **Workman P**, Jones K, Aherne W. Small-Molecule Inhibitors of the Protein Methyltransferase SET7/9 Identified in a High-Throughput Screen. *J Biomol Screen*. 2012; 9; 1102-9.
310. Sharp SY, Roe SM, Kazlauskas E, Cikotienė I, **Workman P**, Matulis D, Prodromou C. Co-crystallization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. *PLoS One*. 2012; 7 9; e44642.
311. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, **Workman P**, Eccles SA, Bayliss R, Linardopoulos S, Blagg J. Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. *J Med Chem*. 2012; 55;8721-34.
312. Patel MN, Halling-Brown, Tym JE, **Workman P**, Al-Lazikani B. Analysis: Objective assessment of cancer genes for drug discovery. *Nature Reviews Drug Discovery*. 2012; 12; 35-50.

PART 2: Reviews

1978

1. **Workman P**, Double JA. Drug latention in cancer chemotherapy. *Biomedicine* 1978; 28:255-62.

1979

2. **Workman P**. Latent drugs for cancer chemotherapy. *Cancer Topics* 1979; 2:6.

1980

3. White RAS, **Workman P**. Pharmacokinetics of misonidazole and other potentially superior radiosensitizing drugs in the dog. *Radiation Sensitizers* 1980:262.
4. **Workman P**. Pharmacokinetics of hypoxic cell radiosensitizers. In: *Radiation Sensitizers*. Brady LW (ed). Mason New York. 1980; p.29.
5. **Workman P**. Pharmacokinetics of hypoxic cell radiosensitizers: A review. *Cancer Clin Trials* 1980; 3:237-51.

1981

6. **Workman P**. Pharmacology of hypoxic cell sensitizers. *Camb Med* 1981; 1:12.

1982

7. **Workman P**. Lipophilicity and the pharmacokinetics of nitroimidazoles. In: *Advanced Topics on Radiosensitizers of Hypoxic Cells*. Breccia A, Rimondi C, Adams GE (eds). Plenum New York. 1982.
8. **Workman P**. Hypoxic cells and cancer therapy. *Cancer Topics* 1982; 4:22.

1983

9. Twentyman PR, **Workman P**. Second UK Workshop on the enhancement of chemotherapy by nitroimidazoles (Meeting Report). *Br J Cancer* 1983; 47:553.
10. **Workman P**. New drugs against hypoxic cells (part 1). *Cancer Topics* 1983; 4:42.
11. **Workman P**. New drugs against hypoxic cells (part 2). *Cancer Topics* 1983; 4:54.
12. **Workman P**. Pharmacokinetics of radiosensitizing agents. In: *Pharmacokinetics of Antitumor Drugs*. Ames MM, Powis G, Kovach JS (eds) Chapter 12. Elsevier Amsterdam. 1983; p.291.

13. **Workman P.** Development of nitroimidazoles. In: The Control of Tumour Growth and Its Biological Bases. Davis W, Maltoni C, Tanneberger S (eds). Akademie-Verlag Berlin. 1983; p.166.

1984

14. Walton MI, Bleehen NM, **Workman P.** The effects of whole-body hyperthermia on the pharmacokinetics of the basic nitroimidazole radiosensitizer Ro 03-8799 in mice. In: Overgaard J, editor. Proceedings of the 4th International Symposium of Hyperthermic Oncology; 1984: Taylor and Francis, London; 1984. p. 417.
15. **Workman P.** British Association of Cancer Research (Meeting Report). Cancer Topics 1984; 5:20.

1985

16. **Workman P.** Radiation therapy. In: The Molecular Basis of Cancer. Farmer P, Walker JM (eds) Chapter 9. Croon Helm Beckenham. 1985; p.237.
17. **Workman P.** British Association for Cancer Research (Meeting Report). Cancer Topics 1985; 5:80.
18. **Workman P,** Lee FYF, Walton MI, Roberts JT, Cheeseman KH, Ahmed I, Bleehen NM. Metabolic aspects of sensitizer development. In: New Chemo and Radiosensitizing Drugs. Breccia A, Fowler JF (eds) Lo Scarabeo, Bologna. 1985; p.91.

1986

19. **Workman P.** The pharmacology of brain tumour chemotherapy. In: Tumours of the Brain. Bleehan N (ed). Chapter 11. Springer-Verlag Berlin. 1986; p.183.
20. **Workman P.** Pharmacokinetics in experimental and clinical chemotherapy. Cancer Chemother Pharmacol 1986; 16:198-9.

1987

21. EORTC Pharmacokinetics and Metabolism Group (Secretary: **P Workman**) Pharmacokinetically guided dose escalation in Phase I clinical trials: Commentary and proposed guidelines. Eur J Cancer 1987; 23:1083.
22. **Workman P.** TCNU: A ray of hope for designer nitrosoureas? Eur J Cancer Clin Oncol 1987; 23:1823-8.
23. **Workman P.** New trends in targeted cancer chemotherapy. In: Drug Delivery in Cancer Treatment. Domellof L (ed). Springer-Verlag Berlin. 1987; p.76.
24. **Workman P,** Lee FYF, Walton MI, Roberts JT, Bleehen NM. Nitroimidazole inhibition of mouse and human cytochrome P-450-mediated hydroxylation of the chloroethylnitrosourea CCNU. In: Drug Metabolism: From Molecules to Man. Benford D, Bridges JW, Gibson GG (eds). Taylor and Francis London. 1987; p.305.

1988

25. UKCCCR Ad Hoc Committee (Chairman: **P Workman**). UKCCCR guidelines for the welfare of animals in experimental neoplasia. Hobbs Southampton. 1988.
26. UKCCCR Ad Hoc Committee (Chairman: **P Workman**). UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988; 22:195-201.
27. UKCCCR Ad Hoc Committee (Chairman: **P Workman**). UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 1988; 58:109.

1989

28. **Workman P.** Micropharmacokinetics of chemical modifiers. *Int J Radiat Oncol Biol Phys* 1989; 16:897-906.
29. **Workman P.** Optimized treatment modalities for hypoxic tumour cells. In: *Drug Delivery in Cancer Treatment II: Symptom Control, Cytokines, Chemotherapy*. Domellof L (ed). Springer-Verlag Berlin. 1989; p.79.
30. **Workman P.** New drugs and novel agents. *Curr Opin Oncol* 1989; 1:213-21.

1990

31. Joint Steering Committee of the EORTC and CRC (Member of EORTC New Drug Development and Co-ordinating Committee and CRC Phase I/II Clinical Trials Subcommittee: **P Workman**). General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. *Eur J Cancer* 1990; 26:411.
32. Powis G, Hickman JA, **Workman P**, Tritton TR, Abita J-P, Berdel WE, Gescher A, Moses HL, Nicolson GL. The cell membrane and cell signals as targets in cancer chemotherapy. *Cancer Res* 1990; 50:2203.
33. Watson JV, Dive C, **Workman P**. Measurement of dynamic cellular events. In: *Methods in Flow Cytometry: A Practical Approach*. Ormerod MG (ed). IRL Press Oxford. 1990; p.241.
34. **Workman P**. Philosophies of new anticancer drug development. *J Drug Dev* 1990; 2:193.
35. **Workman P**. The cell membrane and cell signals: New targets for novel anticancer drugs. *Ann Oncol* 1990; 1:100-11.
36. **Workman P**. Tumours in the brain: A special case for drug delivery. In: *Drug Delivery in Cancer Treatment III Home Care - Symptom Control, Economy, Brain Tumours*. Domellof L (ed). Springer-Verlag Berlin. 1990; p.97.
37. **Workman P**. The cell membrane and cell signals as targets in cancer chemotherapy (Meeting Report). *Eur Cancer News* 1990; 3:3.
38. **Workman P**, Walton MI. Enzyme-directed bioreductive drug development. In: *Selective Activation of Drugs by Redox Processes* Adams GE, Breccia A, Fielden EM, Wardman P (eds). Plenum New York. 1990; p.173.

1991

39. Birchmeier W, Cavalli F, Garattini S, Heldin C-H, Mach J-, monier R, Nusse R, Ponder BAJ, Riethmuller G, Rajewsky MF, Tubiana M, Hansen HH, Aapro MS, Double JA, Gunzburg WH, Helene C, Jahde E, Leake RE, Mantovani A, Pluckthun A, Schwartzmann G, Stevens MFG, **Workman P**, H. Z. (EORTC Scientific Advisory Board). Towards improved cancer diagnosis and treatment founded on current developments in the basic sciences: Options for intensified European efforts. *Eur J Cancer* 1991; 27:936.
40. **Workman P**. Analysis of dynamic events by multiparametric flow cytometry: Flow cytoenzymology of glutathione metabolism using the fluorescent probe monochlorobimane. In: *Trans Royal Microscopical Soc (MICRO 90)*. Chapter 14. IOP Publishing. 1991; p.487.
41. **Workman P**. Antitumor ether lipids: Endocytosis as a determinant of cellular sensitivity. *Cancer Cells* 1991; 3:315-7.

1992

42. Graham MA, **Workman P**. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies. *Ann Oncol* 1992; 3:339-47.
43. Lohmeyer M, **Workman P**. Antitumour ether lipids and platelet-activating factor analogues have different cytotoxic profiles and calcium mobilising effects - A structure-activity study. In: *Proceedings of the 2nd International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury*. Nigan S, Honn KV, Marmett LJ, Walden TL (eds). Kluwer Boston London. 1992; p.699.

44. Riley R, **Workman P**. DT-diaphorase in cancer chemotherapy. *Biochem Pharmacol* 1992; 43:1657-69.
45. Wasserman TH, Siemann D, **Workman P**. Editors' note. Seventh International Conference on Chemical Modifiers of Cancer Treatment. *Int J Radiat Oncol Biol Phys* 1992; 22.
46. **Workman P**. Keynote address: Bioreductive mechanisms. *Int J Radiat Oncol Biol Phys* 1992; 22:631.
47. **Workman P**. Signal transduction inhibitors as novel anticancer drugs: Where are we? *Ann Oncol* 1992; 3:527-31.
48. **Workman P**. Infusional anthracyclines: Is slower better? If so, why? *Ann Oncol* 1992; 3:591-4.
49. **Workman P**. Emerging from a crisis in anticancer drug discovery? Screening versus design: Confessions of an optimistic fence-sitter. *Ann Oncol* 1992; 3:699-705.
50. **Workman P**. Introduction: New anticancer drug design and discovery based on advances in molecular oncology. *Semin Cancer Biol* 1992; 3:329-33.
51. **Workman P**. Introduction. In: *New Development in Cancer Pharmacology: Drug Design and Development I*. **Workman P** (ed). Springer-Verlag Berlin. 1992; p.1.
52. **Workman P**. Design of novel bioreductive drugs. In: *New Developments in Cancer Pharmacology: Drug Design and Development I*. **Workman P** (ed). Springer-Verlag Berlin. 1992; p.63.
53. **Workman P**, D'Incalci M, Berdel WE, Egorin MJ, helene C, Hickman JA, Jarman M, Schwartzmann G, Sikora K. New approaches in cancer pharmacology: Drug design and development. *Eur J Cancer* 1992; 28A:1190.
54. **Workman P**, Kaye SB, Schwartzmann G. Laboratory and phase I studies of new cancer drugs. *Curr Opin Oncol* 1992; 4:1065-72.
55. **Workman P**, Maxwell RJ, Griffiths JR. Non-invasive MRS in new anticancer drug development. *NMR Biomed* 1992; 5:270-2.
56. **Workman P**, Brunton VG, Robins DJ. Tyrosine kinase inhibitors. *Semin Cancer Biol* 1992; 3:369-81.

1993

57. Brunton VG, **Workman P**. Cell-signaling targets for antitumour drug development. *Cancer Chemother Pharmacol* 1993; 32:1-19.
58. Dive C, **Workman P**, Marrone BL, Watson JV. Measurement of enzyme kinetics by flow cytometry. In: *Flow Cytometry: New Developments*. Jacquemin-Sablon A (ed). Springer-Verlag Berlin. 1993; p.29.
59. Graham M, Kerr DJ, **Workman P**. Absorption and distribution of anticancer drugs. In: *Pharmaceutical Aspects of Cancer Chemotherapy, Topics in Pharmacy*. Florence AT, Salole EG (eds). Volume III. Butterworths London. 1993; p.1.
60. Kaye SB, **Workman P**, Graham MA, Cassidy J, Jodrell D. Pharmacokinetics and early clinical studies of selected new drugs. In: *Pharmacokinetics of Cancer Chemotherapy*. **Workman P**, Graham MA (eds). Volume 17, *Cancer Surveys*. Cold Spring Harbor Laboratory Press New York. 1993; p.371-96.
61. Lobbezo MW, Hendriks H, Giaccone GG, **Workman P**. New cytotoxic compounds and new anticancer drug targets. In: *De la Recherche Oncologique a l'Innovation Therapeutique*. Tambourin P, Boiron M (eds). Volume 230. Colloque INSERM/John Libbey Eurotext Ltd. 1993; p.49.
62. Lohmeyer M, **Workman P**. Ether lipids. In: *Handbook of Chemotherapy in Clinical Oncology*. Droz JP, Cvitkovic E, Armand JP, Khoury S (eds). F.I.I.S. 1993; p.400.
63. Reilly JJ, **Workman P**. Normalisation of drug dosage: Some theoretical and practical considerations. *Cancer Chemother Pharmacol* 1993; 32:411-8.
64. Schwartzmann G, **Workman P**. Anticancer drug screening and discovery in the 1990s: A European perspective. *Eur J Cancer* 1993; 29A:3.
65. **Workman P**. New strategies for targeted cancer chemotherapy. *Helix* 1993; 1:50.
66. **Workman P**. Relevance of pharmacology in clinical practice. The moderator thinks that ... *Ann Oncol* 1993; 4:466-9.

67. **Workman P**, Belpomme D, Robert J. New drug design and development in cancer: Present status and future perspectives. *Cancer Chemother Pharmacol* 1993; 32:83-4.
68. **Workman P**. Pharmacokinetics and cancer: Successes, failures and future prospects. In: *Pharmacokinetics of Cancer Chemotherapy*. **Workman P**, Graham MA (eds). Volume 17, *Cancer Surveys*. Cold Spring Harbor Laboratory Press New York. 1993; p.1-26.
69. **Workman P**, Harris AL. Translating advances in molecular oncology into improved therapy: New targets for drug discovery. *Cancer Topics* 1993; 9:97.
70. **Workman P**, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. *Cancer Metastasis Rev* 1993; 12:73-82.

1994

71. Brunton VG, **Workman P**. Protein tyrosine kinase inhibitors as potential cancer drugs. *Cancer Topics* 1994; 10:14.
72. Kerr DJ, **Workman P**. Preface. In: *New Molecular Targets for Cancer Chemotherapy*. Kerr DJ, **Workman P** (eds). CRC Press Boca Raton. 1994.
73. Lee FYF, **Workman P**. Metabolic basis for chemopotential of anticancer drug action by nitroimidazoles. In: *Anticancer Drugs: Reactive Metabolism and Drug Interactions*. Powis G (ed). *International Encyclopaedia of Pharmacology and Therapeutics: Metabolism and Reactions of Anticancer Drugs*. Pergamon Press Oxford. 1994; p.397.
74. Reilly JJ, **Workman P**. Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. *Cancer Chemother Pharmacol* 1994; 34:3-13.
75. Watson JV, Dive C, **Workman P**. Measurement of dynamic cellular events. In: *Flow Cytometry: A Practical Approach*. Ormerod MG (ed). 2nd Edition. IRL Press New York. 1994; p.241.
76. **Workman P**. Enzyme-directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. *Oncol Res* 1994; 6:461-75.
77. **Workman P**. The potential for molecular oncology to define new drug targets. In: *New Molecular Targets for Cancer Chemotherapy*. Kerr DJ, **Workman P** (eds). CRC Press Boca Raton. 1994; p.1.
78. **Workman P**, Brunton VG, Robins DJ. Discovery and design of tyrosine kinase inhibitors. In: *New Developments in Cancer Pharmacology: Drug Design and Development*. **Workman P** (ed). Volume II. Springer-Verlag Berlin. 1994; p.55.
79. **Workman P**, D'Incalci M, Bursch W, Harrap KR, Hawkins RE, Neidle S, Powis G. European School of Oncology Task Force Report. New approaches in cancer pharmacology: Drug design and development (Part 2). *Eur J Cancer* 1994; 30A:1148-60.
80. **Workman P**, Graham MA. Pharmacokinetics and cancer chemotherapy. *Eur J Cancer* 1994; 30A:706-10.

1995

81. Houlihan WJ, Lohmeyer M, **Workman P**, Cheon H. Phospholipid antitumor agents. *Med Res Rev* 1995; 15:157-223.
82. **Workman P**. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? *Hum Exp Toxicol* 1995; 14:222-5.
83. **Workman P**. Bottlenecks in anticancer drug discovery and development: In vivo pharmacokinetic and pharmacodynamic issues and the potential role of PET. . In: *PET for Drug Development and Evaluation* Komar D (ed). Kluwer Dordrecht. 1995; p.277.
84. **Workman P**, Lewis AD, Cassidy J. Alkylating agents and related drugs. In: *Oxford Textbook of Oncology*. Peckham M, Pinedo H, Veronesi U (eds). Oxford University Press Oxford. 1995; p.495.

1996

85. **Workman P.** Cell proliferation, cell cycle and apoptosis targets for cancer drug discovery: Strategies, strengths and pitfalls. In: Apoptosis and Cell Cycle Control Basic Mechanisms and Implications for Treating Malignant Disease Bios Scientific Publishers Oxford. 1996; p.205.

1997

86. UKCCCR Ad Hoc Committee (Chairman: **P Workman**). UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). 1997.
87. **Workman P.** The changing delivery of healthcare: New molecular targets for cancer chemotherapy. ID Weekly Highlights, Current Drugs Ltd 1997; 45:24-7.
88. **Workman P.** Towards intelligent anticancer drug screening in the post-genome era? Anticancer Drug Des 1997; 12:525-31.

1998

89. Stratford IJ, **Workman P.** Bioreductive drugs into the next millennium. Anticancer Drug Des 1998; 13:519-28.
90. **Workman P.** Cancer research in the clinic: Translating modern research into clinical reality. ID Weekly Highlights, Current Drugs Ltd 1998; 3:17-20.
91. **Workman P,** Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition). Br J Cancer 1998; 77:1-10.

1999

92. Garrett MD, **Workman P.** Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999; 35:2010-30.
93. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, **Workman P.** Anticancer agents targeting signalling molecules and cancer cell environment: Challenges for drug development? J Natl Cancer Inst 1999; 91:1281-7.
94. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (**P Workman** Member of Committee). United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group Workshop. Br J Cancer 1999; 79:2-3.
95. **Workman P.** Emerging molecular therapies: small molecule drugs. In: The Molecular Manual of Cancer. 1999.
96. **Workman P.** The impact of biotechnology on the discovery of new anticancer drugs. Helix 1999.
97. **Workman P.** Where are the drugs of the future? Cancer Topics 1999; 11:15-9.
98. **Workman P.** Shaping drug discovery for the future. Drug discovery at the CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton. In: CRC Scientific Yearbook 1998-1999. CRC London. 1999; p.24-6.
99. **Workman P,** Cassidy J. New drug discovery and development. In: Oxford Textbook of Oncology. 1999.

2000

100. **Workman P.** Biotechnology and the discovery of new anticancer drugs. Part 1: Locating new targets. Helix 2000; 1:31-3.
101. **Workman P.** Biotechnology and the discovery of new anticancer drugs Part 2: From genes to drugs. Helix 2000; 2:32-3.
102. **Workman P.** Overcoming cross-talk related signalling in tumours with therapeutic agents. Pezcoller Foundation Year 7 2000; Number 15:16-7.

103. **Workman P.** Signal transduction pathways: A goldmine for therapeutic targets. In: Farnesyltransferase and Geranylgeranyltransferase. Sebti S, Hamilton A (eds). Humana Press New Jersey. 2000; p.1.
104. **Workman P.** Towards genomic cancer pharmacology: Innovative drugs for the new millenium. *Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs* 2000; 2:21-5.
105. **Workman P.** Towards intelligent drug design in the post-genome era? *Anticancer Drug Des* 2000; 1386:525-31.
106. **Workman P.** Drugs and genomics. WHO Web Site http://www.who.int/ncd/cancer/publications/abstracts/abs9810_20.html 2000.
107. **Workman P.** New Targets Committee. In: *The Cancer Research Campaign Scientific Yearbook 2000-01*. CRC London, UK. 2000; p.54-6.
108. **Workman P.** Emerging molecular therapies: Small molecule drugs. In: *Principles of Molecular Oncology*. Bronchud M, Foote MA, Peters WP, Robinson MO (eds). Humana Press New Jersey. 2000; p.421.
109. **Workman P** (interviewed by D Bonn). At the cutting edge of drug discovery. *Lancet Oncol* 2000; 2:113-8.

2001

110. Anderson H, Price P, Blomley M, Leach MO, **Workman P.** Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. *Br J Cancer* 2001; 85:1085-93.
111. Clarke PA, te Poele R, Wooster R, **Workman P.** Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential. *Biochem Pharmacol* 2001; 62:1311-36.
112. **Workman P.** New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. *Curr Cancer Drug Targets* 2001; 1:33-47.
113. **Workman P.** Scoring a bull's-eye against cancer genome targets. *Curr Opin Pharmacol* 2001; 1:342-52.
114. **Workman P.** Changing times: Developing cancer drugs in genomeland. *Curr Opin Invest Drugs* 2001; 2:1128-35.
115. **Workman P,** Clarke PA. New cancer drug targets: Genomics, transcriptomics and clinomics. *Expert Opin Pharmacother* 2001; 2:911-5.

2002

116. Aherne GW, McDonald E, **Workman P.** Finding the needle in the haystack: Why high throughput screening is good for your health. *Breast Cancer Res Treat* 2002; 4:148-54.
117. Aherne W, Garrett MD, McDonald E, **Workman P.** Mechanism-based high-throughput screening for novel anticancer drug discovery. In: *Anticancer Drug Development*. Baguley BC, Kerr DJ (eds) Chapter 14. Academic Press San Diego. 2002; p.249-67.
118. Aherne W, Rowlands MG, Stimson L, **Workman P.** Assays for the identification and evaluation of histone acetyltransferase inhibitors. *Methods* 2002; 26:245-53.
119. Kaye SB, **Workman P.** Signal transduction pathway signalling. In: *Cancer Handbook*. Alison M (ed). Chapter 96. Nature Publishing Group. 2002; p.1497-505.
120. Maloney A, **Workman P.** Hsp90 as a new therapeutic target for cancer therapy: The story unfolds. *Expert Opin Biol Ther* 2002; 2:3-24.
121. **Workman P.** Cancer genome targets: Raf-ing up tumour cell to overcome oncogene addiction. *Expert Rev Anticancer Ther* 2002; 2:611-4.
122. **Workman P.** Challenges of PK/PD measurements in modern drug development. *Eur J Cancer* 2002; 38:2189-93.
123. **Workman P.** Pharmacogenomics in cancer drug discovery and development: Inhibitors of the Hsp90 molecular chaperone. *Cancer Detect Prev* 2002; 26:405-10.
124. **Workman P.** The impact of genomic and proteomic technologies on the development of new cancer drugs. *Ann Oncol* 2002; 13:115-24.

125. **Workman P.** Novel therapeutic strategies. In: Oxford Textbook of Oncology. Cassidy J, Bissett D, Spence RAJ (eds) Chapter 40. Oxford University Press Oxford. 2002; p.638-53.
126. **Workman P.** Priorities for cancer research in the 21st century: Translating the cancer genome into new cancer therapies. *The Vista de Oncologia* 2002; 4:4.
127. **Workman P.** Cancer - 21st century solutions. *Biotechnology Investment Today* 2002; 1.
128. **Workman P.** From cancer genomics to new cancer therapeutics. *Eur J Hum Genet* 2002; 10:56.
129. **Workman P,** Kaye SB. Translating basic cancer research into new cancer therapies. *Trends Mol Med* 2002; 8:S1-S9.

2003

130. Aherne W, **Workman P.** Screening for novel anticancer drugs in an academic environment: The right time and the right place? *Trends in Drug Discovery* 2003; 4:44-7.
131. Banerji U, Judson I, **Workman P.** The clinical applications of heat shock protein inhibitors in cancer - present and future. *Curr Cancer Drug Targets* 2003; 32:385-90.
132. Garrett MD, Walton MI, McDonald E, Judson I, **Workman P.** The contemporary drug development process: Advances and challenges in preclinical and clinical development. In: *Progress in Cell Cycle Research*. Meijer L, Jezequel A, Roberge M (eds). Volume 5 Chapter 14. 2003; p.145-58.
133. Garrett MD, **Workman P.** Design of drugs targeting the cell cycle. In: *Targeted Cancer Therapies: An Odyssey*. Bruland O, Flaegstad T (eds). PDC Tangen. 2003; p.84-90.
134. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, **Workman P.** Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. *Br J Radiol* 2003; 76:S87-S91.
135. Maloney A, Clarke PA, **Workman P.** Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: A mechanistic perspective. *Curr Cancer Drug Targets* 2003; 3:331-42.
136. Pestell KE, **Workman P.** Paul Workman on the challenges of cancer drug development. *Drug Discov Today* 2003; 8:775-7.
137. Seddon BM, **Workman P.** The role of functional and molecular imaging in cancer drug discovery and development. *Br J Radiol* 2003; 76:S128-S38.
138. te Poele R, **Workman P.** Genomics and drug development. In: *Anticancer Drug Development*. Budman DR, Calvert AH, Rowinsky EK (eds) Chapter 8. Lippincott Williams & Wilkins Baltimore, Maryland. 2003; p.97-115.
139. **Workman P.** Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. *Mol Cancer Ther* 2003; 2:131-8.
140. **Workman P.** Preface. *Curr Cancer Drug Targets* 2003; 3:i.
141. **Workman P.** Overview: Translating Hsp90 biology into Hsp90 drugs. *Curr Cancer Drug Targets* 2003:297-300.
142. **Workman P.** How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. *Curr Pharm Design* 2003; 9:891-902.
143. **Workman P.** Strategies for treating cancers caused by multiple genome abnormalities. From concepts to cures? *Curr Opin Invest Drugs* 2003;4:1410-5.
144. **Workman P.** The opportunities and challenges of personalised genome-based molecular therapies for cancer: targets, technologies and molecular chaperones. *Cancer Chemother Pharmacol* 2003; 52:45-56.
145. **Workman P.** Hsp90 molecular chaperone inhibitors: Opportunities and challenges. *Curr Cancer Drug Targets* 2003; 3. 297-300.
146. **Workman P.** Interview by Pestell KE: Paul Workman on the challenges of cancer drug development. *Drug Discov Today* 2003; 8:775-7.

2004

147. Baird R, **Workman P**. Emerging molecular therapies: Drugs interfering with signal transduction pathways. In: Principles of Molecular Oncology. Bronchud M, Foote MA, Giaccone B (eds), 2nd Edition Chapter 18. Humana Press Totowa, New Jersey. 2004; p.569-606.
148. Banerji U, **Workman P**. Molecular targets. In: Handbook of Pharmacokinetics and Pharmacodynamics. Figg WD, McLeod HL (eds). Humana Press Totowa. 2004.
149. Clarke PA, te Poele R, **Workman P**. Gene expression microarray technologies in the development of new therapeutic agents. *Eur J Cancer* 2004; 40:2560-91.
150. Dymock B, Drysdale M, McDonald E, **Workman P**. Inhibitors of Hsp90 and other chaperones for the treatment of cancer. *Expert Opinion on Therapeutic Patents* 2004; 14:837-47.
151. Jackman AL, Kaye S, **Workman P**. The combination of cytotoxic and molecularly targeted therapies - can it be done? *Drug Discov Today* 2004; 4:445-54.
152. Kristeleit R, Stimson L, **Workman P**, Aherne W. Histone modification enzymes: Novel targets for cancer drugs. *Expert Opin Emerg Drugs* 2004; 9:135-54.
153. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, **Workman P**. Assessment of antiangiogenic and antivasular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. *Br J Radiol* 2004; 76:S87-S91.
154. Seddon B, Kelland LR, **Workman P**. Bioreductive prodrugs for cancer therapy. In: Methods in Molecular Medicine - Suicide Gene Therapy. Springer CJ (ed). Volume 90. Humana Press Inc Totowa, New Jersey. 2004; p.515-42.
155. te Poele R, Clarke PA, **Workman P**. Gene microarray technologies for cancer drug discovery and development. In: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. Prendergast GC (ed). Volume Second Edition Chapter 8. Wiley-Liss Hoboken, New Jersey. 2004; p.142-82.
156. **Workman P**. Altered states: selectively drugging the Hsp90 cancer chaperone. *Trends Mol Med* 2004; 10:47-51.
157. **Workman P**. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. *Cancer Lett* 2004; 206:149-57.
158. **Workman P**. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. *Biochem Soc Trans* 2004; 32:393-6.
159. **Workman P**. Genome-based cancer drug development: From theory to practice. Evolving genetics and its global impact. In: Proceedings of the Fifth Princess Chulabhorn International Science Congress. Amarin Printing and Publishing Company Bangkok. 2004; p.221-6.
160. **Workman P**. Pharmacological intervention with multistep oncogenesis: Potential role for HSP90 inhibitors. In: Cancer Chemoprevention. Kedoff GJ, Hawk ET, Sigman CC (eds). Volume 1, Promising Cancer Chemoprevention Agents. Humana Press Totowa. 2004; p.325-37.
161. **Workman P**. Drug discovery strategies: technologies to accelerate translation from target to drug. *J Chemotherapy* 2004; 16:13-5.

2005

162. Benson C, Kaye S, **Workman P**, Garrett M, Walton M, de Bono J. Clinical anticancer drug development: targeting the cyclin-dependent kinases. *Br J Cancer* 2005; 92:7-12.
163. Clarke PA, Powers M, **Workman P**. Inhibition of the molecular chaperone Hsp90 in cancer: Consequences for the regulation of survival signalling and induction of cell death. In: Apoptosis & Cancer Therapy. Debatin KM, Fulda S (eds). Wiley-vch. 2005.
164. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, **Workman P**. The assessment of antiangiogenic and antivasular therapeutics in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. *Br J Cancer* 2005; 92:1599-610.
165. **Workman P**. Genomics and the second golden era of cancer drug development. *Mol BioSyst* 2005; 1:17-26.

166. **Workman P**, Pacey S, Banerji U, Judson I. Hsp90 inhibitors in the clinics. *Molecular Chaperones in Health and Disease: Handbook of Experimental Pharmacology*, 331-358 Vol. 172 Gaestel, Matthias (Ed.) 2006.
167. **Workman P**. Biomarkers for molecular therapeutics: The pharmacologic audit trail. *Current Challenges and Novel Approaches to Modern Cancer Drug Discovery 2005*; Extended Abstracts for the 35th International Symposium of the Princess Takaamatsu Cancer Research Fund, 2004, Tokyo:81-96.
168. **Workman P**. New cancer drugs on the horizon. *Future Oncol* 2005; 1:315-8.
169. **Workman P**. Technologies to accelerate the discovery of molecular therapeutics. *Ann Oncol* 2005; 16:15.
170. **Workman P**. Drugging the cancer kinome: Successes, problems and emerging solutions. In: *Am Soc Clin Oncol Educational Book*. ISSN 1548-8748. 2005; p.950-60.
171. **Workman P**, Johnston P. Genomic profiling of cancer: What next? *J Clin Oncol* 2005; 23:7253-6.

2006

172. Collins I, **Workman P**. Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets. *Curr Signal Trans Ther* 2006; 1:13-23.
173. Collins I, **Workman P**. New approaches to molecular cancer therapeutics. *Nat Chem Biol* 2006; 2:689-700.
174. McDonald E, Jones K, Brough PA, Drysdale MJ, **Workman P**. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. *Curr Top Med Chem* 2006; 6:1193-203.
175. McDonald E, **Workman P**, Jones K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. *Curr Top Med Chem* 2006; 6:1091-107.
176. Pacey S, Banerji U, Judson I, **Workman P**. Hsp90 inhibitors in the clinic. In: *Handbook of Experimental Pharmacology: Molecular Chaperones in Health and Disease*. Gaestel M (ed). Volume 172. Springer-Verlag Berlin, Heidelberg. 2006; p.331-58.
177. Powers M, **Workman P**. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. *Endocr-Relat Cancer* 2006; 13:S125-S35.
178. Sharp S, **Workman P**. Inhibitors of the HSP90 molecular chaperone: current status. *Adv Cancer Res* 2006; 95:323-48.
179. **Workman P**. Drugging the cancer kinome: progress and challenges in developing personalised molecular cancer therapeutics. *Cold Spring Harbor Symposium on Quantitative Biology Molecular Approaches to Controlling Cancer* 2006; 70:499-515.
180. **Workman P**. Using biomarkers in drug development. *Clin Adv Hematol Oncol* 2006; 4:736-9.
181. **Workman P**, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, Zweit J, Cancer Research UK Pharmacodynamic Pharmacokinetic Technologies Advisory Committee. Minimally-invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. *J Natl Cancer Inst* 2006; 98:580-98.
182. **Workman P**, Clarke PA. Hot off the Press: Global gene expression signatures for global chemical probe and drug discovery. *Mol BioSyst* 2006; 2:605-8.
183. **Workman P**, Clarke PA. Global gene expression signatures for global chemical probe and drug discovery. *Mol BioSyst* 2006; 2:605-8.
184. **Workman P**, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. *Nat Biotechnol* 2006; 24:794-6.

2007

185. Collins I, Molife R, Kaye SB, **Workman P**. Rational drug design of small molecule anticancer agents: Preclinical discovery. In: *The Cancer Handbook 2nd Edition*. Alison MR (ed). John Wiley & Sons Ltd. Chichester, UK. 2007; p.1199-215.

186. Garret MD, Raynaud F, **Workman P**, Aherne W, Eccles SA. Application of meso scale technology for the measurement of phosphoproteins in human tumour xenografts. *Assay Drug Dev Technol* 2007; 5:391-401.
187. Molife R, Collins I, Kaye SB, **Workman P**. Rational drug design of small molecule anticancer agents: Early clinical development. In: *Cancer Handbook 2nd Edition*. Alison MR (ed). John Wiley & Sons Ltd. Chichester, UK. 2007; p.1216-41.
188. Powers MV, **Workman P**. Inhibitors of the heat shock response: Biology and pharmacology. *FEBS Lett* 2007; 581:3758-69.
189. Sarker D, Pacey S, **Workman P**. Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. *Biomark Med* 2007; 1:399-417.
190. Sarker D, **Workman P**. Pharmacodynamic biomarkers for molecular cancer therapeutics. *Adv Cancer Res* 2007; 96:213-68.
191. Sharp SY, Jones K, **Workman P**. HSP90 inhibitors: Targeting the cancer chaperone for combinatorial blockade of oncogenic pathways. In: *Cancer Drug Design and Discovery*. Neidle S (ed). Academic Press London. 2007; p.305-35.
192. Smith JR, **Workman P**. Targeting the cancer chaperone HSP90. *Drug Discovery Today: Therapeutic Strategies* 2007; 4:219-27.
193. Smith NF, Raynaud FI, **Workman P**. The application of cassette dosing for pharmacokinetic screening of small-molecule cancer drug discovery. *Mol Cancer Ther* 2007; 6:428-40.
194. **Workman P**. Drugging the cancer genome: New challenges of infrequent and combinatorial targets. *Curr Opin Invest Drugs* 2007; 8:445-6.
195. **Workman P**, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. *Ann N Y Acad Sci* 2007; 1113:202-16.
196. **Workman P**, Collins I. Modern cancer drug discovery: Integrating targets, technologies and treatments. In: *Cancer Drug Design and Discovery*. Neidle S (ed). Academic Press. 2007; p.3-38.
197. **Workman P**, de Billy E. Putting the heat on cancer. *Nat Med* 2007; 13:1415-7.
198. **Workman P**, Powers MV. Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer. *Nat Chem Biol* 2007; 3:455-7.
199. **Workman P**, Sharp S. Targeting Hsp90: The cancer super-chaperone. In: *Targeted Therapies in Oncology*. Giaccone G, Soria JC (eds). Informa Healthcare. 2007; p.373-98.

2008

200. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, **Workman P**. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. *Gynecol Oncol* 2008; 108:652-7.
201. Banerji U, de Bono J, Judson I, Kaye S, **Workman P**. Biomarkers in early clinical trials: The committed and the skeptics. *Clin Cancer Res* 2008; 14:2512-3.
202. Holmes JL, Sharp SY, **Workman P**. Drugging the HSP90 molecular chaperone machine for cancer treatment. In: *Heat Shock Proteins in Cancer*. Calderwood SK, Sherman MY, Ciocca DR (eds). Springer. 2008; p.295-329.
203. Pearl LH, Prodromou C, **Workman P**. The Hsp90 molecular chaperone: an open and shut case for treatment. *Biochem J* 2008; 410:439-53.
204. Reid AHM, Baird R, **Workman P**. Emerging molecular therapeutics: Drugs interfering with signal transduction pathways. In: *Principles of Molecular Oncology*. Bronchud MH, Foote M, Giaccone G, Olopade O (eds). Volume Third Edition. Humana Press Totowa, New Jersey. 2008; p.317-65.
205. **Workman P**, de Bono J. Targeted therapeutics for cancer treatment: Major progress towards personalised molecular medicine. *Curr Opin Pharmacol* 2008; 8:359-62.
206. Yap TA, Garrett MD, Walton M, Raynaud F, de Bono JS, **Workman P**. Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls and promises. *Curr Opin Pharmacol* 2008; 8:393-412.

2009

207. Carden CP, Banerji U, Kaye S, **Workman P**, De Bono J. From darkness to light with biomarkers in early clinical trials of cancer drugs. *Clin Pharmacol Ther* 2009; 85:131-3.
208. Pacey S, Sarker D, **Workman P**. Pharmacokinetics and pharmacodynamics in drug development. In: *Encyclopedia of Cancer*, 2nd Edition. Schwab M (ed). Volume 3. Springer-Verlag, Berlin, Heidelberg, New York. 2009; p.2306-9.
209. Powers M, **Workman P**. HSP90 inhibition as an anticancer strategy: Novel approaches and future directions. In: *Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and Their Potential as Targets*. Hiscox S, Gee J, Nicholson RI (eds). Springer Publishing. 2009; p.111-37.
210. Powers MV, **Workman P**. Molecular chaperones. In: *Encyclopedia of Cancer*, 2nd Edition. Schwab M (ed). Volume 3. Springer-Verlag, Berlin, Heidelberg, New York. 2009; p.1934-5.
211. Powers MV, Clarke PA, **Workman P**. Extra View: Death by chaperone. HSP90, HPS70 or both? *Cell Cycle* 2009; 8:518-26
212. van Montfort RLM, **Workman P**. Structure-based design of molecular cancer therapeutics. *Trends in Biotechnology* 2009; 27:315-28.
213. **Workman P**. Drugging the cancer genome. *Drug Discovery Today*, July 2009. <http://newsletter.drugdiscoverytoday.com/generated/default/f14/theview.htm>
214. Smith JR, **Workman P**. Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning. *Cell Cycle* 2009; 8:362-72.
215. de Billy E, Powers MV, Smith JR, **Workman P**. Drugging the heat shock factor 1 pathway: Exploitation of the critical cancer cell dependence on the guardian of the proteome. *Cell Cycle* 2009; 8:3806-08.
216. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, **Workman P**. Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. *Cancer J* 2009; 15:406-20

2010

217. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, **Workman P**, Kaye SB, de Bono JS. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? *Drug Discov Today* 2010;15:88-97.
218. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RLM, **Workman P**. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? *Cell Cycle* 2010; 9:1542-1550.
219. **Workman P**, Clarke PA, Raynaud FI, van Montfort RLM. Drugging the PI3 kinome: From chemical tools to drugs in the clinic. *Cancer Res* 2010; 70:2146-2157.
220. **Workman P**, Travers J. Drug-tolerant insurgents. *Nature* 2010; 464: 844-45.
221. **Workman P**, van Montfort RLM. PI(3) Kinases: Revealing the delta lady. *Nat Chem Biol* 2010; 6:82-3.
222. **Workman P**, van Montfort RLM. Unveiling the secrets of the ancestral PI3 kinase Vps34: New mechanistic insights and prospects for designing probes and drugs. *Cancer Cell* 2010;17:421-23.
223. **Workman P**, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. Guidelines for the welfare and use of animals in cancer research. *Br J Cancer* 2010; 102:1555-77.
224. **Workman P**, Collins I. Probing the probes: fitness factors for small molecule tools. *Chem Biol*. 2010;17:561-77.
225. Yap TA, Sandhu SK, **Workman P**, de Bono JS. Envisioning the future of early anticancer drug development. *Nat Rev Cancer*. 2010;10:514-23.

2011

226. **Workman P**, Clarke PA. Resisting Targeted Therapy: Fifty ways to leave your EGFR. *Cancer Cell*. 2011; 19:437-40.
227. **Workman P**, Davies FE. A stressful life (or death): Combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability. *Oncotarget*. 2011; 4:277-80.
228. Darby JF, Workman P. Chemical biology: Many faces of a cancer-supporting protein. *Nature* 2011; 478:334-5.
229. Raynaud FI, **Workman P**. Discovering and developing PI3 kinase inhibitors for cancer: rapid progress through academic-biotech-pharma interactions. *Mol Cancer Ther*. 2011;10:2017-8.
230. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, **Workman P**. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. *Curr Med Chem*. 2011; 18:2686-714.
231. Travers J, Blagg J, **Workman P**. Epigenetics: Targeting leukemia on the DOT. *Nat Chem Biol*. 2011; 7:663-5.

2012

232. Clarke PA, **Workman P**. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. *J Clin Oncol*. 2012; 30:331-3.
233. **Workman P**, Clarke PA, Al-Lazikani B. Personalized medicine: patient-predictive panel power. *Cancer Cell*. 2012; 21:455-8.
234. Hoelder S, Clarke PA, **Workman P**. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. *Mol Oncol*. 2012 2:155-76.
235. Neckers L, **Workman P**. Hsp90 molecular chaperone inhibitors: are we there yet? *Clin Cancer Res*. 2012; 18:1:64-76.
236. Samant RS, Clarke PA, **Workman P**. The expanding proteome of the molecular chaperone HSP90. *Cell Cycle*. 2012;11:1301-8.
237. Travers J, Sharp S, **Workman P**. HSP90 inhibition: two-pronged exploitation of cancer dependencies. *Drug Discov Today*. 2012;17:242-52.
238. Yap TA, **Workman P**. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. *Annu Rev Pharmacol Toxicol*. 2012; 52:549-73.
239. **Workman P**, Clarke P: From PI3 Kinase in Cancer: From Biology to Clinic. 2012 ASCO Educational Book.
240. Alexander Pintzas, Boris Zhivotovsky, **Paul Workman**, Paul A. Clarke, Spiros Linardopoulos, Jean-Claude Martinou, Juan Carlos Lacal, Sylvie Robine, George Nasioulas and Ladislav Andera. Sensitization of (colon) cancer cells to death receptor related therapies. *Cancer Biology & Therapy* 2012;13:7; 458-466.
241. Al-Lazikani B, Banerji U, **Workman P**. Combinatorial drug therapy for cancer in the post-genomic era. *Nat Biotechnol* 2012;10:30;679-692.
242. de Billy E, Travers J, **Workman P**. Shock about heat shock in cancer. *Oncotarget* 2012; 8; 741-3.
243. Samant R, **Workman P**. Choose your protein partners. *Nature* 2012; 490:351-2.
244. Pintzas A, Zhivotovsky B, **Workman P**, Clarke PA, Linardopoulos S, Martinou JC, Lacal JC, Robine S, Nasioulas G, Andera L. Sensitization of (colon) cancer cells to death receptor related therapies. *Cancer Biology & Therapy* 2012; 13: 458-466.
245. Martins AS, Davies FE, **Workman P**. Inhibiting the molecular evolution of cancer through HSP90. *Oncotarget* 2012; 10:1054-6.
246. Castro de Gonzalez D, Clarke PA, Al-Lazikani B, **Workman P**. Personalized cancer medicine: Molecular diagnostics, predictive biomarkers and drug resistance. *Clinical Pharmacology & Therapeutics*. 2012.

2013

247. Al-Lazikani B, **Workman P**. Unpicking the combination lock for mutant BRAF and RAS melanomas. *Cancer Discovery*. 2013; 3:14-9.

PART 3: Books

1992

1. **Workman P**, (Ed). New Approaches in Cancer Pharmacology: Drug Design and Development Volume 1. Springer-Verlag, Berlin, 1992.

1993

2. **Workman P**, MA Graham (Guest Eds). Pharmacokinetics of Cancer Chemotherapy. Cancer Surveys, Volume 17, Cold Spring Harbor Laboratory Press, New York, 1993.

1994

3. **Workman P**, (Ed). New Approaches in Cancer Pharmacology: Drug Design and Development. Volume II. Springer-Verlag, Berlin, 1994.
4. Kerr DJ, **Workman P**. New Molecular Targets for Cancer Chemotherapy. CRC Press Boca Raton. 1994.

2004

5. Bronchud M, Foote MA, Giaccone B, Olufunmilayo O, **Workman P**. Principles of Molecular Oncology. Second Edition. Humana Press Inc Totowa, New Jersey, 2004.

2008

6. Bronchud M, Foote MA, Olufunmilayo O, **Workman P**. Principles of Molecular Oncology. Third Edition. Humana Press, Totowa, New Jersey 2008.

Part 4: Edited Journal Issues

1992

1. Wasserman TH, Siemann D, **Workman P** (Guest Eds). Chemical Modifiers of Cancer Treatment. Collected papers from Seventh International Conference on Chemical Modifiers of Cancer Treatment. Part 1. Int J Radiat Oncol Biol Phys 1992; 22.
2. Wasserman TH, Siemann D, **Workman P** (Guest Eds). Chemical Modifiers of Cancer Treatment. Collected papers from Seventh International Conference on Chemical Modifiers of Cancer Treatment. Part 2. Int J Radiat Oncol Biol Phys 1992; 22.
3. **Workman P** (Guest Ed). New Anticancer Drug Development Based on Advances in Molecular Oncology. Semin Cancer Biol 1992; 3.

1993

4. **Workman P**, Graham MA (Guest eds). Pharmacokinetics of Cancer Chemotherapy. Volume 17. Cold Spring Harbor Laboratory Press New York. 1993.
5. Stratford IJ, Workman P Eds). Bioreductive Drugs for Cancer Therapy. Cancer Metastasis Rev 1993; 12.

1994

Professor Paul Workman PhD DSc (Hon) FMedSci FSB FRSC

6. Powis G, **Workman P**. Signalling targets for the development of cancer drugs. *Anticancer Drug Des* 1994; 9:555-68.

1996

7. Stratford IJ, **Workman P**, Coleman N (Guest Eds). Chemical Modifiers of Cancer Treatment. *Br J Cancer* 1996; 74.

2002

8. **Workman P**, Kaye SB (Guest Eds). Trends Guide to Cancer Therapeutics. Supplement to *Trends in Molecular Medicine* 2002.

2003

9. **Workman P** (Guest Ed). Hsp90 molecular chaperone inhibitors: Opportunities and challenges. *Curr Cancer Drug Targets* 2003; 3.

2005

10. **Workman P**, Johnston PG (Guest Eds). Molecular Oncology and Genomics. *J Clin Oncol* 2005; 23.